1
|
Danckaert A, Trignol A, Le Loher G, Loubens S, Staels B, Duez H, Shorte SL, Mayeuf-Louchart A. MuscleJ2: a rebuilding of MuscleJ with new features for high-content analysis of skeletal muscle immunofluorescence slides. Skelet Muscle 2023; 13:14. [PMID: 37612778 PMCID: PMC10463807 DOI: 10.1186/s13395-023-00323-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Accepted: 07/25/2023] [Indexed: 08/25/2023] Open
Abstract
Histological analysis of skeletal muscle is of major interest for understanding its behavior in different pathophysiological conditions, such as the response to different environments or myopathies. In this context, many software programs have been developed to perform automated high-content analysis. We created MuscleJ, a macro that runs in ImageJ/Fiji on batches of images. MuscleJ is a multianalysis tool that initially allows the analysis of muscle fibers, capillaries, and satellite cells. Since its creation, it has been used in many studies, and we have further developed the software and added new features, which are presented in this article. We converted the macro into a Java-language plugin with an improved user interface. MuscleJ2 provides quantitative analysis of fibrosis, vascularization, and cell phenotype in whole muscle sections. It also performs analysis of the peri-myonuclei, the individual capillaries, and any staining in the muscle fibers, providing accurate quantification within regional sublocalizations of the fiber. A multicartography option allows users to visualize multiple results simultaneously. The plugin is freely available to the muscle science community.
Collapse
Affiliation(s)
- Anne Danckaert
- UTechS Photonic BioImaging/C2RT, Institut Pasteur, Université Paris Cité, 75015, Paris, France.
| | - Aurélie Trignol
- French Armed Forces Biomedical Research Institute - IRBA, Brétigny-sur-Orge, France
| | - Guillaume Le Loher
- UTechS Photonic BioImaging/C2RT, Institut Pasteur, Université Paris Cité, 75015, Paris, France
- École Centrale d'Electronique (ECE), Paris, France
| | - Sébastien Loubens
- CHU Lille, INSERM, Institut Pasteur de Lille, Univ. Lille, U1011-EGID, Lille, 59000, France
- Service Neuropédiatrie, CHU Lille, 59000, Lille, France
| | - Bart Staels
- CHU Lille, INSERM, Institut Pasteur de Lille, Univ. Lille, U1011-EGID, Lille, 59000, France
| | - Hélène Duez
- CHU Lille, INSERM, Institut Pasteur de Lille, Univ. Lille, U1011-EGID, Lille, 59000, France
| | - Spencer L Shorte
- UTechS Photonic BioImaging/C2RT, Institut Pasteur, Université Paris Cité, 75015, Paris, France
| | - Alicia Mayeuf-Louchart
- CHU Lille, INSERM, Institut Pasteur de Lille, Univ. Lille, U1011-EGID, Lille, 59000, France.
| |
Collapse
|
2
|
Vinod M, Berthier A, Maréchal X, Gheeraert C, Boutry R, Delhaye S, Annicotte JS, Duez H, Hovasse A, Cianférani S, Montaigne D, Eeckhoute J, Staels B, Lefebvre P. Timed use of digoxin prevents heart ischemia-reperfusion injury through a REV-ERBα-UPS signaling pathway. Nat Cardiovasc Res 2022; 1:990-1005. [PMID: 38229609 PMCID: PMC7615528 DOI: 10.1038/s44161-022-00148-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Accepted: 09/16/2022] [Indexed: 01/18/2024]
Abstract
Myocardial ischemia-reperfusion injury (MIRI) induces life-threatening damages to the cardiac tissue and pharmacological means to achieve cardioprotection are sorely needed. MIRI severity varies along the day-night cycle and is molecularly linked to components of the cellular clock including the nuclear receptor REV-ERBα, a transcriptional repressor. Here we show that digoxin administration in mice is cardioprotective when timed to trigger REV-ERBα protein degradation. In cardiomyocytes, digoxin increases REV-ERBα ubiquitinylation and proteasomal degradation, which depend on REV-ERBα ability to bind its natural ligand, heme. Inhibition of the membrane-bound Src tyrosine-kinase partially alleviated digoxin-induced REV-ERBα degradation. In untreated cardiomyocytes, REV-ERBα proteolysis is controlled by known (HUWE1, FBXW7, SIAH2) or novel (CBL, UBE4B) E3 ubiquitin ligases and the proteasome subunit PSMB5. Only SIAH2 and PSMB5 contributed to digoxin-induced degradation of REV-ERBα. Thus, controlling REV-ERBα proteostasis through the ubiquitin-proteasome system is an appealing cardioprotective strategy. Our data support the timed use of clinically-approved cardiotonic steroids in prophylactic cardioprotection.
Collapse
Affiliation(s)
- Manjula Vinod
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France
| | - Alexandre Berthier
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France
| | - Xavier Maréchal
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France
| | - Céline Gheeraert
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France
| | - Raphaёl Boutry
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 – RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000 Lille, France
| | - Stéphane Delhaye
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France
| | - Jean-Sébastien Annicotte
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167 – RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F-59000 Lille, France
| | - Hélène Duez
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France
| | - Agnès Hovasse
- Laboratoire de Spectrométrie de Masse BioOrganique (LSMBO), IPHC, Université de Strasbourg, CNRS, UMR7178, 25 Rue Becquerel, F-67087 Strasbourg, France
| | - Sarah Cianférani
- Laboratoire de Spectrométrie de Masse BioOrganique (LSMBO), IPHC, Université de Strasbourg, CNRS, UMR7178, 25 Rue Becquerel, F-67087 Strasbourg, France
| | - David Montaigne
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France
| | - Jérôme Eeckhoute
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France
| | - Bart Staels
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France
| | - Philippe Lefebvre
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France
| |
Collapse
|
3
|
Duez H, Pourcet B. Récepteurs nucléaires et rythmes circadiens. Med Sci (Paris) 2022; 38:669-678. [DOI: 10.1051/medsci/2022102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
L’horloge circadienne programme l’ensemble des processus physiologiques, dont l’activité du système immunitaire, à des moments précis de la journée. Elle permet d’optimiser les fonctions de l’organisme en anticipant les changements quotidiens tels que les cycles jour/nuit. Nos habitudes de vie comme l’exposition à la lumière artificielle ou une prise alimentaire irrégulière désynchronisent cependant cette horloge et provoquent des maladies, par exemple inflammatoires. Au niveau moléculaire, elle consiste en un réseau de facteurs de transcription dont certains sont des récepteurs nucléaires, activables par des ligands. Une meilleure compréhension des rythmes biologiques et du rôle des récepteurs nucléaires de l’horloge circadienne permettrait d’ouvrir un champ thérapeutique nouveau. La chronothérapie qui consiste en l’administration d’un composé pharmacologique au moment de la journée le plus propice, permettrait, en ciblant ces récepteurs, d’optimiser l’efficacité du traitement et d’en réduire les possibles effets secondaires.
Collapse
|
4
|
Fougeray T, Polizzi A, Régnier M, Fougerat A, Ellero-Simatos S, Lippi Y, Smati S, Lasserre F, Tramunt B, Huillet M, Dopavogui L, Salvi J, Nédélec E, Gigot V, Smith L, Naylies C, Sommer C, Haas JT, Wahli W, Duez H, Gourdy P, Gamet-Payrastre L, Benani A, Burnol AF, Loiseau N, Postic C, Montagner A, Guillou H. The hepatocyte insulin receptor is required to program the liver clock and rhythmic gene expression. Cell Rep 2022; 39:110674. [PMID: 35417722 DOI: 10.1016/j.celrep.2022.110674] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Revised: 02/03/2022] [Accepted: 03/23/2022] [Indexed: 12/30/2022] Open
Abstract
Liver physiology is circadian and sensitive to feeding and insulin. Food intake regulates insulin secretion and is a dominant signal for the liver clock. However, how much insulin contributes to the effect of feeding on the liver clock and rhythmic gene expression remains to be investigated. Insulin action partly depends on changes in insulin receptor (IR)-dependent gene expression. Here, we use hepatocyte-restricted gene deletion of IR to evaluate its role in the regulation and oscillation of gene expression as well as in the programming of the circadian clock in the adult mouse liver. We find that, in the absence of IR, the rhythmicity of core-clock gene expression is altered in response to day-restricted feeding. This change in core-clock gene expression is associated with defective reprogramming of liver gene expression. Our data show that an intact hepatocyte insulin receptor is required to program the liver clock and associated rhythmic gene expression.
Collapse
Affiliation(s)
- Tiffany Fougeray
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, 31027 Toulouse, France; Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, 1 Avenue Jean Poulhès, BP 84225, 31432 Toulouse, France
| | - Arnaud Polizzi
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, 31027 Toulouse, France
| | - Marion Régnier
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, 31027 Toulouse, France
| | - Anne Fougerat
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, 31027 Toulouse, France
| | - Sandrine Ellero-Simatos
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, 31027 Toulouse, France
| | - Yannick Lippi
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, 31027 Toulouse, France
| | - Sarra Smati
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, 31027 Toulouse, France; Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, 1 Avenue Jean Poulhès, BP 84225, 31432 Toulouse, France; Université de Nantes, INSERM, CNRS, CHU Nantes, Institut du Thorax, 44000 Nantes, France
| | - Frédéric Lasserre
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, 31027 Toulouse, France
| | - Blandine Tramunt
- Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, 1 Avenue Jean Poulhès, BP 84225, 31432 Toulouse, France; Service de Diabétologie, Maladies Métaboliques et Nutrition, CHU de Toulouse, Université de Toulouse, Toulouse, France
| | - Marine Huillet
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, 31027 Toulouse, France
| | - Léonie Dopavogui
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, 31027 Toulouse, France
| | - Juliette Salvi
- Centre des Sciences du Goût et de l'Alimentation, CNRS, INRAE, Université Bourgogne Franche-Comté, Institut Agro Dijon, 21000 Dijon, France
| | - Emmanuelle Nédélec
- Centre des Sciences du Goût et de l'Alimentation, CNRS, INRAE, Université Bourgogne Franche-Comté, Institut Agro Dijon, 21000 Dijon, France
| | - Vincent Gigot
- Centre des Sciences du Goût et de l'Alimentation, CNRS, INRAE, Université Bourgogne Franche-Comté, Institut Agro Dijon, 21000 Dijon, France
| | - Lorraine Smith
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, 31027 Toulouse, France
| | - Claire Naylies
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, 31027 Toulouse, France
| | - Caroline Sommer
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, 31027 Toulouse, France
| | - Joel T Haas
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France
| | - Walter Wahli
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, 31027 Toulouse, France; Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore 308232, Singapore; Center for Integrative Genomics, University of Lausanne, Le Génopode, 1015 Lausanne, Switzerland
| | - Hélène Duez
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France
| | - Pierre Gourdy
- Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, 1 Avenue Jean Poulhès, BP 84225, 31432 Toulouse, France; Service de Diabétologie, Maladies Métaboliques et Nutrition, CHU de Toulouse, Université de Toulouse, Toulouse, France
| | - Laurence Gamet-Payrastre
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, 31027 Toulouse, France
| | - Alexandre Benani
- Centre des Sciences du Goût et de l'Alimentation, CNRS, INRAE, Université Bourgogne Franche-Comté, Institut Agro Dijon, 21000 Dijon, France
| | | | - Nicolas Loiseau
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, 31027 Toulouse, France
| | - Catherine Postic
- Université de Paris, Institut Cochin, CNRS, INSERM, 75014 Paris, France
| | - Alexandra Montagner
- Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, 1 Avenue Jean Poulhès, BP 84225, 31432 Toulouse, France.
| | - Hervé Guillou
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, 31027 Toulouse, France.
| |
Collapse
|
5
|
Abstract
The modern way of life has dramatically affected our biological rhythms. Circadian rhythms, which are generated by an endogenous circadian clock, are observed in a large number of physiological functions including metabolism. Proper peripheral clock synchronization by different signals including appropriate feeding/fasting cycles is essential to coordinate and temporally gate metabolic processes. In this chapter, we emphasize the importance of nutrient sensing by peripheral clocks and highlight the major role of peripheral and central clock communication to locally regulate metabolic processes and ensure optimal energy storage and expenditure. As a consequence, changes in eating behavior and/or bedtime, as occurs upon shift work and jet lag, have direct consequences on metabolism and participate in the increasing prevalence of obesity and associated metabolic diseases such as type 2 diabetes and non-alcoholic fatty liver disease. In this setting, time-restricted feeding has been suggested as an efficient approach to ameliorate metabolic parameters and control body weight.
Collapse
Affiliation(s)
- Yasmine Sebti
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France
| | - Aurore Hebras
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France
| | - Benoit Pourcet
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France
| | - Bart Staels
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France.
| | - Hélène Duez
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France
| |
Collapse
|
6
|
Abstract
The innate immune system is the first line of defense specialized in the clearing of invaders whether foreign elements like microbes or self-elements that accumulate abnormally including cellular debris. Inflammasomes are master regulators of the innate immune system, especially in macrophages, and are key sensors involved in maintaining cellular health in response to cytolytic pathogens or stress signals. Inflammasomes are cytoplasmic complexes typically composed of a sensor molecule such as NOD-Like Receptors (NLRs), an adaptor protein including ASC and an effector protein such as caspase 1. Upon stimulation, inflammasome complex components associate to promote the cleavage of the pro-caspase 1 into active caspase-1 and the subsequent activation of pro-inflammatory cytokines including IL-18 and IL-1β. Deficiency or overactivation of such important sensors leads to critical diseases including Alzheimer diseases, chronic inflammatory diseases, cancers, acute liver diseases, and cardiometabolic diseases. Inflammasomes are tightly controlled by a two-step activation regulatory process consisting in a priming step, which activates the transcription of inflammasome components, and an activation step which leads to the inflammasome complex formation and the subsequent cleavage of pro-IL1 cytokines. Apart from the NF-κB pathway, nuclear receptors have recently been proposed as additional regulators of this pathway. This review will discuss the role of nuclear receptors in the control of the NLRP3 inflammasome and the putative beneficial effect of new modulators of inflammasomes in the treatment of inflammatory diseases including colitis, fulminant hepatitis, cardiac ischemia-reperfusion and brain diseases.
Collapse
|
7
|
Mayeuf-Louchart A, Lancel S, Sebti Y, Pourcet B, Loyens A, Delhaye S, Duhem C, Beauchamp J, Ferri L, Thorel Q, Boulinguiez A, Zecchin M, Dubois-Chevalier J, Eeckhoute J, Vaughn LT, Roach PJ, Dani C, Pederson BA, Vincent SD, Staels B, Duez H. Glycogen Dynamics Drives Lipid Droplet Biogenesis during Brown Adipocyte Differentiation. Cell Rep 2020; 29:1410-1418.e6. [PMID: 31693883 PMCID: PMC7057258 DOI: 10.1016/j.celrep.2019.09.073] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Revised: 08/02/2019] [Accepted: 09/25/2019] [Indexed: 12/20/2022] Open
Abstract
Browning induction or transplantation of brown adipose tissue (BAT) or brown/beige adipocytes derived from progenitor or induced pluripotent stem cells (iPSCs) can represent a powerful strategy to treat metabolic diseases. However, our poor understanding of the mechanisms that govern the differentiation and activation of brown adipocytes limits the development of such therapy. Various genetic factors controlling the differentiation of brown adipocytes have been identified, although most studies have been performed using in vitro cultured pre-adipocytes. We investigate here the differentiation of brown adipocytes from adipose progenitors in the mouse embryo. We demonstrate that the formation of multiple lipid droplets (LDs) is initiated within clusters of glycogen, which is degraded through glycophagy to provide the metabolic substrates essential for de novo lipogenesis and LD formation. Therefore, this study uncovers the role of glycogen in the generation of LDs. Brown adipocytes are functionally differentiated at E17.5 in the mouse embryo Lipid droplets are formed within glycogen clusters Glycogen production is crucial for lipid droplet biogenesis during BAT differentiation Glycophagy-mediated glycogen degradation drives lipid droplet formation
Collapse
Affiliation(s)
- Alicia Mayeuf-Louchart
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France.
| | - Steve Lancel
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France
| | - Yasmine Sebti
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France
| | - Benoit Pourcet
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France
| | - Anne Loyens
- Univ. Lille, UMR-S 1172-JPArc Centre de Recherche Jean-Pierre Aubert Neurosciences et Cancer, Lille, France
| | - Stéphane Delhaye
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France
| | - Christian Duhem
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France
| | - Justine Beauchamp
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France
| | - Lise Ferri
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France
| | - Quentin Thorel
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France
| | - Alexis Boulinguiez
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France
| | - Mathilde Zecchin
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France
| | - Julie Dubois-Chevalier
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France
| | - Jérôme Eeckhoute
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France
| | - Logan T Vaughn
- Indiana University School of Medicine-Muncie and Ball State University, Muncie, IN 47306, USA
| | - Peter J Roach
- Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Christian Dani
- Université Côte d'Azur, CNRS, INSERM, iBV Faculté de Médecine, Nice, France
| | - Bartholomew A Pederson
- Indiana University School of Medicine-Muncie and Ball State University, Muncie, IN 47306, USA
| | - Stéphane D Vincent
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France; Centre National de la Recherche Scientifique, UMR7104, Illkirch, France; Institut National de la Santé et de la Recherche Médicale, U1258 Illkirch, France; Université de Strasbourg, Illkirch, France
| | - Bart Staels
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France
| | - Hélène Duez
- Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France
| |
Collapse
|
8
|
Abstract
The innate immune system senses “non-self” molecules derived from pathogens (PAMPs) as well as endogenous damage-associated molecular patterns (DAMPs) and promotes sterile inflammation that is necessary for injury resolution, tissue repair/regeneration, and homeostasis. The NOD-, LRR- and pyrin domain containing protein 3 (NLRP3) is an innate immune signaling complex whose assembly and activation can be triggered by various signals ranging from microbial molecules to ATP or the abnormal accumulation of crystals, thus leading to IL-1β and IL-18 maturation and secretion. Deregulation of the NLRP3 signaling cascade is associated with numerous inflammatory and metabolic diseases including rheumatoid arthritis, gout, atherosclerosis or type 2 diabetes. Interestingly, the circadian clock controls numerous inflammatory processes while clock disruption leads to or exacerbates inflammation. Recently, the biological clock was demonstrated to control NLRP3 expression and activation, thereby controlling IL-1β and IL-18 secretion in diverse tissues and immune cells, particularly macrophages. Circadian oscillations of NLRP3 signaling is lost in models of clock disruption, contributing to the development of peritonitis, hepatitis, or colitis. Sterile inflammation is also an important driver of atherosclerosis, and targeting the production of IL-1β has proven to be a promising approach for atherosclerosis management in humans. Interestingly, the extent of injury after fulminant hepatitis or myocardial infarction is time-of-day dependent under the control of the clock, and chronotherapy represents a promising approach for the management of pathologies involving deregulation of NLRP3 signaling.
Collapse
Affiliation(s)
- Benoit Pourcet
- University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France
| | - Hélène Duez
- University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France
| |
Collapse
|
9
|
Mayeuf-Louchart A, Duez H. [From glycogen to lipid droplet: an intimate connection in the brown adipocyte]. Med Sci (Paris) 2020; 36:577-579. [PMID: 32614307 DOI: 10.1051/medsci/2020102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Alicia Mayeuf-Louchart
- Université de Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- Institut Européen de Génomique du Diabète (EGID), 1 rue du Pr Calmette, F-59019 Lille, France
| | - Hélène Duez
- Université de Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- Institut Européen de Génomique du Diabète (EGID), 1 rue du Pr Calmette, F-59019 Lille, France
| |
Collapse
|
10
|
Marciniak C, Duhem C, Boulinguiez A, Raverdy V, Baud G, Verkindt H, Caiazzo R, Staels B, Duez H, Pattou F, Lancel S. Differential unfolded protein response in skeletal muscle from non-diabetic glucose tolerant or intolerant patients with obesity before and after bariatric surgery. Acta Diabetol 2020; 57:819-826. [PMID: 32086613 DOI: 10.1007/s00592-020-01490-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2019] [Accepted: 01/21/2020] [Indexed: 01/08/2023]
Abstract
AIMS Not all people with obesity become glucose intolerant, suggesting differential activation of cellular pathways. The unfolded protein response (UPR) may contribute to the development of insulin resistance in several organs, but its role in skeletal muscle remains debated. Therefore, we explored the UPR activation in muscle from non-diabetic glucose tolerant or intolerant patients with obesity and the impact of bariatric procedures. METHODS Muscle biopsies from 22 normoglycemic (NG, blood glucose measured 120 min after an oral glucose tolerance test, G120 < 7.8 mM) and 22 glucose intolerant (GI, G120 between 7.8 and 11.1 mM) patients with obesity were used to measure UPR activation by RTqPCR and western blot. Then, UPR was studied in biopsies from 7 NG and 7 GI patients before and 1 year after bariatric surgery. RESULTS Binding immunoglobulin protein (BIP) protein was ~ 40% higher in the GI compared to NG subjects. Contrastingly, expression of the UPR-related genes BIP, activating transcription factor 6 (ATF6) and unspliced X-box binding protein 1 (XBP1u) were significantly lower and C/EBP homologous protein (CHOP) tended to decrease (p = 0.08) in GI individuals. While BIP protein positively correlated with fasting blood glucose (r = 0.38, p = 0.01), ATF6 and CHOP were associated with G120 (r = - 0.38 and r = - 0.41, p < 0.05) and the Matsuda index (r = 0.37 and r = 0.38, p < 0.05). Bariatric surgery improved metabolic parameters, associated with higher CHOP expression in GI patients, while ATF6 tended to increase (p = 0.08). CONCLUSIONS CHOP and ATF6 expression decreased in non-diabetic GI patients with obesity and was modified by bariatric surgery. These genes may contribute to glucose homeostasis in human skeletal muscle.
Collapse
Affiliation(s)
- Camille Marciniak
- Univ. Lille, Inserm, CHU Lille, U1190 - EGID, F-59000, Lille, France
| | - Christian Duhem
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
| | - Alexis Boulinguiez
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
| | - Violeta Raverdy
- Univ. Lille, Inserm, CHU Lille, U1190 - EGID, F-59000, Lille, France
| | - Gregory Baud
- Univ. Lille, Inserm, CHU Lille, U1190 - EGID, F-59000, Lille, France
| | - Hélène Verkindt
- Univ. Lille, Inserm, CHU Lille, U1190 - EGID, F-59000, Lille, France
| | - Robert Caiazzo
- Univ. Lille, Inserm, CHU Lille, U1190 - EGID, F-59000, Lille, France
| | - Bart Staels
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
| | - Hélène Duez
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
| | - François Pattou
- Univ. Lille, Inserm, CHU Lille, U1190 - EGID, F-59000, Lille, France
| | - Steve Lancel
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France.
| |
Collapse
|
11
|
Bernard A, Dastugue A, Maquart G, Delhaye S, Duez H, Besnard P. Diet-Induced Obesity Alters the Circadian Expression of Clock Genes in Mouse Gustatory Papillae. Front Physiol 2020; 11:726. [PMID: 32714209 PMCID: PMC7344166 DOI: 10.3389/fphys.2020.00726] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2020] [Accepted: 06/04/2020] [Indexed: 12/29/2022] Open
Abstract
Diet-induced obesity (DIO) is associated with a defect of the orosensory detection of dietary lipids in rodents. This dysfunction is not anecdotic since it might worsen the negative effects of obesity by promoting the overconsumption of energy-dense foods. Previous studies have highlighted a progressive devaluation of reward value of lipid stimuli due to a desensitization of dopaminergic brain areas in DIO mice. Paradoxically, the putative deleterious impact of obesity on peripheral fat detection by the gustatory papillae remains poorly documented. Using a whole transcriptomic investigation of the circumvallate papillae (CVP), an analysis of CVP genes involved in fat taste transduction and signaling along the day, and two bottle choice tests, we have found that (i) CVP, known to house the most taste buds in the oral cavity, displays a genic circadian rhythm, (ii) DIO reduces the oscillation of key genes involved both in the circadian clock and lipid detection/signaling, and (iii) the gene invalidation of the clock gene Rev-Erbα does not significantly affect fat preference despite an oily solution intake slightly lower than littermate controls. Taken together these data bring the first demonstration that the gustatory function is under control of a peripheral clock in mammals, as already reported in fly and suggest that a disturbance of this rhythmicity might contribute to the lower fatty taste acuity found in obese mice.
Collapse
Affiliation(s)
- Arnaud Bernard
- UMR Lipide/Nutrition/Cancer, 1231 Inserm/University Bourgogne Franche-Comté, Dijon, France
| | - Aurélie Dastugue
- UMR Lipide/Nutrition/Cancer, 1231 Inserm/University Bourgogne Franche-Comté, Dijon, France
| | - Guillaume Maquart
- UMR Lipide/Nutrition/Cancer, 1231 Inserm/University Bourgogne Franche-Comté, Dijon, France
| | - Stéphane Delhaye
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France
| | - Hélène Duez
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France
| | - Philippe Besnard
- UMR Lipide/Nutrition/Cancer, 1231 Inserm/University Bourgogne Franche-Comté, Dijon, France
- *Correspondence: Philippe Besnard,
| |
Collapse
|
12
|
Dubois V, Gheeraert C, Vankrunkelsven W, Dubois‐Chevalier J, Dehondt H, Bobowski‐Gerard M, Vinod M, Zummo FP, Güiza F, Ploton M, Dorchies E, Pineau L, Boulinguiez A, Vallez E, Woitrain E, Baugé E, Lalloyer F, Duhem C, Rabhi N, van Kesteren RE, Chiang C, Lancel S, Duez H, Annicotte J, Paumelle R, Vanhorebeek I, Van den Berghe G, Staels B, Lefebvre P, Eeckhoute J. Endoplasmic reticulum stress actively suppresses hepatic molecular identity in damaged liver. Mol Syst Biol 2020; 16:e9156. [PMID: 32407006 PMCID: PMC7224309 DOI: 10.15252/msb.20199156] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Revised: 04/09/2020] [Accepted: 04/14/2020] [Indexed: 02/06/2023] Open
Abstract
Liver injury triggers adaptive remodeling of the hepatic transcriptome for repair/regeneration. We demonstrate that this involves particularly profound transcriptomic alterations where acute induction of genes involved in handling of endoplasmic reticulum stress (ERS) is accompanied by partial hepatic dedifferentiation. Importantly, widespread hepatic gene downregulation could not simply be ascribed to cofactor squelching secondary to ERS gene induction, but rather involves a combination of active repressive mechanisms. ERS acts through inhibition of the liver-identity (LIVER-ID) transcription factor (TF) network, initiated by rapid LIVER-ID TF protein loss. In addition, induction of the transcriptional repressor NFIL3 further contributes to LIVER-ID gene repression. Alteration to the liver TF repertoire translates into compromised activity of regulatory regions characterized by the densest co-recruitment of LIVER-ID TFs and decommissioning of BRD4 super-enhancers driving hepatic identity. While transient repression of the hepatic molecular identity is an intrinsic part of liver repair, sustained disequilibrium between the ERS and LIVER-ID transcriptional programs is linked to liver dysfunction as shown using mouse models of acute liver injury and livers from deceased human septic patients.
Collapse
Affiliation(s)
- Vanessa Dubois
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
- Present address:
Clinical and Experimental EndocrinologyDepartment of Chronic Diseases, Metabolism and Ageing (CHROMETA)KU LeuvenLeuvenBelgium
| | - Céline Gheeraert
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| | - Wouter Vankrunkelsven
- Clinical Division and Laboratory of Intensive Care MedicineDepartment of Cellular and Molecular MedicineKU LeuvenLeuvenBelgium
| | | | - Hélène Dehondt
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| | | | - Manjula Vinod
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| | | | - Fabian Güiza
- Clinical Division and Laboratory of Intensive Care MedicineDepartment of Cellular and Molecular MedicineKU LeuvenLeuvenBelgium
| | - Maheul Ploton
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| | - Emilie Dorchies
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| | - Laurent Pineau
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| | - Alexis Boulinguiez
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| | - Emmanuelle Vallez
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| | - Eloise Woitrain
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| | - Eric Baugé
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| | - Fanny Lalloyer
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| | - Christian Duhem
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| | - Nabil Rabhi
- UMR 8199 ‐ EGIDCNRSInstitut Pasteur de LilleUniversity of LilleLilleFrance
| | - Ronald E van Kesteren
- Center for Neurogenomics and Cognitive ResearchNeuroscience Campus AmsterdamVU UniversityAmsterdamThe Netherlands
| | - Cheng‐Ming Chiang
- Simmons Comprehensive Cancer CenterDepartments of Biochemistry and PharmacologyUniversity of Texas Southwestern Medical CenterDallasTXUSA
| | - Steve Lancel
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| | - Hélène Duez
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| | | | - Réjane Paumelle
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| | - Ilse Vanhorebeek
- Clinical Division and Laboratory of Intensive Care MedicineDepartment of Cellular and Molecular MedicineKU LeuvenLeuvenBelgium
| | - Greet Van den Berghe
- Clinical Division and Laboratory of Intensive Care MedicineDepartment of Cellular and Molecular MedicineKU LeuvenLeuvenBelgium
| | - Bart Staels
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| | - Philippe Lefebvre
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| | - Jérôme Eeckhoute
- Inserm, CHU LilleInstitut Pasteur de LilleU1011‐EGIDUniversity of LilleLilleFrance
| |
Collapse
|
13
|
Sebti Y, Ferri L, Zecchin M, Beauchamp J, Mogilenko D, Staels B, Duez H, Pourcet B. The LPS/D-Galactosamine-Induced Fulminant Hepatitis Model to Assess the Role of Ligand-Activated Nuclear Receptors on the NLRP3 Inflammasome Pathway In Vivo. Methods Mol Biol 2019; 1951:189-207. [PMID: 30825154 DOI: 10.1007/978-1-4939-9130-3_15] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
The NLRP3 inflammasome is a cellular sensor of danger signals such as extracellular ATP or abnormally accumulating molecules like crystals. Activation of NLRP3 by such compounds triggers a sterile inflammatory response that may be involved in numerous pathologies including rheumatoid arthritis, atherosclerosis, diabetes, and Alzheimer's disease. A better understanding of the mechanisms that govern NLRP3 inflammasome activation is an important step toward the development of novel therapeutic strategies to dampen over-activation of the immune system. Recent findings demonstrate that ligand-activated nuclear receptors regulate the NLRP3 inflammasome pathway, thus representing possible therapeutic targets. It is therefore important to assess the potential of these putative targets in the regulation of the NLRP3 inflammasome activation in the most appropriate pathophysiological models. Fulminant hepatitis (FH) results from massive hepatocyte apoptosis, hemorrhagic necrosis, and inflammation. Low doses of LPS in combination with the specific hepatotoxic agent D-galactosamine (D-GalN) promote liver injury in mice and induce the production of inflammatory cytokines associated with increased NLRP3 protein and caspase 1 activity, thus recapitulating the clinical picture of FH in humans. We provide a simple method to examine the involvement of nuclear receptors in NLRP3-driven fulminant hepatitis, consisting in the induction of FH, in the isolation of liver macrophages, and in the extraction and analysis of RNA content.
Collapse
Affiliation(s)
- Yasmine Sebti
- European Genomic Institute for Diabetes (E.G.I.D.), Lille, France
- UNIV LILLE, Lille, France
- INSERM UMR 1011, Lille, France
- CHU Lille, Lille, France
- Institut Pasteur de Lille, Lille, France
| | - Lise Ferri
- European Genomic Institute for Diabetes (E.G.I.D.), Lille, France
- UNIV LILLE, Lille, France
- INSERM UMR 1011, Lille, France
- CHU Lille, Lille, France
- Institut Pasteur de Lille, Lille, France
| | - Mathilde Zecchin
- European Genomic Institute for Diabetes (E.G.I.D.), Lille, France
- UNIV LILLE, Lille, France
- INSERM UMR 1011, Lille, France
- CHU Lille, Lille, France
- Institut Pasteur de Lille, Lille, France
| | - Justine Beauchamp
- European Genomic Institute for Diabetes (E.G.I.D.), Lille, France
- UNIV LILLE, Lille, France
- INSERM UMR 1011, Lille, France
- CHU Lille, Lille, France
- Institut Pasteur de Lille, Lille, France
| | - Denis Mogilenko
- European Genomic Institute for Diabetes (E.G.I.D.), Lille, France
- UNIV LILLE, Lille, France
- INSERM UMR 1011, Lille, France
- CHU Lille, Lille, France
- Institut Pasteur de Lille, Lille, France
| | - Bart Staels
- European Genomic Institute for Diabetes (E.G.I.D.), Lille, France
- UNIV LILLE, Lille, France
- INSERM UMR 1011, Lille, France
- CHU Lille, Lille, France
- Institut Pasteur de Lille, Lille, France
| | - Hélène Duez
- European Genomic Institute for Diabetes (E.G.I.D.), Lille, France
- UNIV LILLE, Lille, France
- INSERM UMR 1011, Lille, France
- CHU Lille, Lille, France
- Institut Pasteur de Lille, Lille, France
| | - Benoit Pourcet
- European Genomic Institute for Diabetes (E.G.I.D.), Lille, France.
- UNIV LILLE, Lille, France.
- INSERM UMR 1011, Lille, France.
- CHU Lille, Lille, France.
- Institut Pasteur de Lille, Lille, France.
| |
Collapse
|
14
|
Berthier A, Vinod M, Porez G, Steenackers A, Alexandre J, Yamakawa N, Gheeraert C, Ploton M, Maréchal X, Dubois-Chevalier J, Hovasse A, Schaeffer-Reiss C, Cianférani S, Rolando C, Bray F, Duez H, Eeckhoute J, Lefebvre T, Staels B, Lefebvre P. Combinatorial regulation of hepatic cytoplasmic signaling and nuclear transcriptional events by the OGT/REV-ERBα complex. Proc Natl Acad Sci U S A 2018; 115:E11033-E11042. [PMID: 30397120 PMCID: PMC6255172 DOI: 10.1073/pnas.1805397115] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
The nuclear receptor REV-ERBα integrates the circadian clock with hepatic glucose and lipid metabolism by nucleating transcriptional comodulators at genomic regulatory regions. An interactomic approach identified O-GlcNAc transferase (OGT) as a REV-ERBα-interacting protein. By shielding cytoplasmic OGT from proteasomal degradation and favoring OGT activity in the nucleus, REV-ERBα cyclically increased O-GlcNAcylation of multiple cytoplasmic and nuclear proteins as a function of its rhythmically regulated expression, while REV-ERBα ligands mostly affected cytoplasmic OGT activity. We illustrate this finding by showing that REV-ERBα controls OGT-dependent activities of the cytoplasmic protein kinase AKT, an essential relay in insulin signaling, and of ten-of-eleven translocation (TET) enzymes in the nucleus. AKT phosphorylation was inversely correlated to REV-ERBα expression. REV-ERBα enhanced TET activity and DNA hydroxymethylated cytosine (5hmC) levels in the vicinity of REV-ERBα genomic binding sites. As an example, we show that the REV-ERBα/OGT complex modulates SREBP-1c gene expression throughout the fasting/feeding periods by first repressing AKT phosphorylation and by epigenomically priming the Srebf1 promoter for a further rapid response to insulin. Conclusion: REV-ERBα regulates cytoplasmic and nuclear OGT-controlled processes that integrate at the hepatic SREBF1 locus to control basal and insulin-induced expression of the temporally and nutritionally regulated lipogenic SREBP-1c transcript.
Collapse
Affiliation(s)
- Alexandre Berthier
- University of Lille, Inserm, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, European Genomic Institute for Diabetes, U1011, Lille F-59045, France
| | - Manjula Vinod
- University of Lille, Inserm, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, European Genomic Institute for Diabetes, U1011, Lille F-59045, France
| | - Geoffrey Porez
- University of Lille, Inserm, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, European Genomic Institute for Diabetes, U1011, Lille F-59045, France
| | - Agata Steenackers
- University of Lille, CNRS, Unité de Glycobiologie Structurale et Fonctionnelle, UMR 8576, Villeneuve d'Ascq F-59655, France
| | - Jérémy Alexandre
- University of Lille, Inserm, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, European Genomic Institute for Diabetes, U1011, Lille F-59045, France
| | - Nao Yamakawa
- University of Lille, CNRS, Unité de Glycobiologie Structurale et Fonctionnelle, UMR 8576, Villeneuve d'Ascq F-59655, France
| | - Céline Gheeraert
- University of Lille, Inserm, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, European Genomic Institute for Diabetes, U1011, Lille F-59045, France
| | - Maheul Ploton
- University of Lille, Inserm, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, European Genomic Institute for Diabetes, U1011, Lille F-59045, France
| | - Xavier Maréchal
- University of Lille, Inserm, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, European Genomic Institute for Diabetes, U1011, Lille F-59045, France
| | - Julie Dubois-Chevalier
- University of Lille, Inserm, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, European Genomic Institute for Diabetes, U1011, Lille F-59045, France
| | - Agnès Hovasse
- Laboratoire de Spectrométrie de Masse BioOrganique, University of Strasbourg, CNRS, Institut Pluridisciplinaire Hubert Curien, UMR 7178, Strasbourg F-67037, France
| | - Christine Schaeffer-Reiss
- Laboratoire de Spectrométrie de Masse BioOrganique, University of Strasbourg, CNRS, Institut Pluridisciplinaire Hubert Curien, UMR 7178, Strasbourg F-67037, France
| | - Sarah Cianférani
- Laboratoire de Spectrométrie de Masse BioOrganique, University of Strasbourg, CNRS, Institut Pluridisciplinaire Hubert Curien, UMR 7178, Strasbourg F-67037, France
| | - Christian Rolando
- Miniaturisation pour la Synthèse, l'Analyse & la Protéomique, CNRS, Unité de Service et de Recherche (USR) 3290, University of Lille, Villeneuve d'Ascq F-59655, France
- Fédération de Recherche Biochimie Structurale et Fonctionnelle des Assemblages Biomoléculaires FRABio, FR 3688 CNRS, University of Lille, Villeneuve d'Ascq F-59655, France
- Institut M.-E. Chevreul, CNRS, FR 2638, University of Lille, Villeneuve d'Ascq F-59655, France
| | - Fabrice Bray
- Miniaturisation pour la Synthèse, l'Analyse & la Protéomique, CNRS, Unité de Service et de Recherche (USR) 3290, University of Lille, Villeneuve d'Ascq F-59655, France
- Fédération de Recherche Biochimie Structurale et Fonctionnelle des Assemblages Biomoléculaires FRABio, FR 3688 CNRS, University of Lille, Villeneuve d'Ascq F-59655, France
- Institut M.-E. Chevreul, CNRS, FR 2638, University of Lille, Villeneuve d'Ascq F-59655, France
| | - Hélène Duez
- University of Lille, Inserm, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, European Genomic Institute for Diabetes, U1011, Lille F-59045, France
| | - Jérôme Eeckhoute
- University of Lille, Inserm, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, European Genomic Institute for Diabetes, U1011, Lille F-59045, France
| | - Tony Lefebvre
- University of Lille, CNRS, Unité de Glycobiologie Structurale et Fonctionnelle, UMR 8576, Villeneuve d'Ascq F-59655, France
| | - Bart Staels
- University of Lille, Inserm, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, European Genomic Institute for Diabetes, U1011, Lille F-59045, France
| | - Philippe Lefebvre
- University of Lille, Inserm, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, European Genomic Institute for Diabetes, U1011, Lille F-59045, France;
| |
Collapse
|
15
|
Mayeuf-Louchart A, Hardy D, Thorel Q, Roux P, Gueniot L, Briand D, Mazeraud A, Bouglé A, Shorte SL, Staels B, Chrétien F, Duez H, Danckaert A. MuscleJ: a high-content analysis method to study skeletal muscle with a new Fiji tool. Skelet Muscle 2018; 8:25. [PMID: 30081940 PMCID: PMC6091189 DOI: 10.1186/s13395-018-0171-0] [Citation(s) in RCA: 92] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2018] [Accepted: 07/20/2018] [Indexed: 11/22/2022] Open
Abstract
Background Skeletal muscle has the capacity to adapt to environmental changes and regenerate upon injury. To study these processes, most experimental methods use quantification of parameters obtained from images of immunostained skeletal muscle. Muscle cross-sectional area, fiber typing, localization of nuclei within the muscle fiber, the number of vessels, and fiber-associated stem cells are used to assess muscle physiology. Manual quantification of these parameters is time consuming and only poorly reproducible. While current state-of-the-art software tools are unable to analyze all these parameters simultaneously, we have developed MuscleJ, a new bioinformatics tool to do so. Methods Running on the popular open source Fiji software platform, MuscleJ simultaneously analyzes parameters from immunofluorescent staining, imaged by different acquisition systems in a completely automated manner. Results After segmentation of muscle fibers, up to three other channels can be analyzed simultaneously. Dialog boxes make MuscleJ easy-to-use for biologists. In addition, we have implemented color in situ cartographies of results, allowing the user to directly visualize results on reconstituted muscle sections. Conclusion We report here that MuscleJ results were comparable to manual observations made by five experts. MuscleJ markedly enhances statistical analysis by allowing reliable comparison of skeletal muscle physiology-pathology results obtained from different laboratories using different acquisition systems. Providing fast robust multi-parameter analyses of skeletal muscle physiology-pathology, MuscleJ is available as a free tool for the skeletal muscle community. Electronic supplementary material The online version of this article (10.1186/s13395-018-0171-0) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Alicia Mayeuf-Louchart
- Inserm, CHU Lille, Institut Pasteur de Lille, University of Lille, U1011 - EGID, 1 rue du Pr. Calmette, F-59000, Lille, France.
| | - David Hardy
- Experimental Neuropathology Unit, Infection and Epidemiology Department, Institut Pasteur, 25, rue du Docteur Roux, 75015, Paris, France
| | - Quentin Thorel
- Inserm, CHU Lille, Institut Pasteur de Lille, University of Lille, U1011 - EGID, 1 rue du Pr. Calmette, F-59000, Lille, France
| | - Pascal Roux
- UTechS PBI (Imagopole)-Citech, Institut Pasteur, 25, rue du Docteur Roux, 75015, Paris, France
| | - Lorna Gueniot
- Experimental Neuropathology Unit, Infection and Epidemiology Department, Institut Pasteur, 25, rue du Docteur Roux, 75015, Paris, France
| | - David Briand
- Experimental Neuropathology Unit, Infection and Epidemiology Department, Institut Pasteur, 25, rue du Docteur Roux, 75015, Paris, France
| | - Aurélien Mazeraud
- Experimental Neuropathology Unit, Infection and Epidemiology Department, Institut Pasteur, 25, rue du Docteur Roux, 75015, Paris, France
| | - Adrien Bouglé
- Experimental Neuropathology Unit, Infection and Epidemiology Department, Institut Pasteur, 25, rue du Docteur Roux, 75015, Paris, France
| | - Spencer L Shorte
- UTechS PBI (Imagopole)-Citech, Institut Pasteur, 25, rue du Docteur Roux, 75015, Paris, France
| | - Bart Staels
- Inserm, CHU Lille, Institut Pasteur de Lille, University of Lille, U1011 - EGID, 1 rue du Pr. Calmette, F-59000, Lille, France
| | - Fabrice Chrétien
- Experimental Neuropathology Unit, Infection and Epidemiology Department, Institut Pasteur, 25, rue du Docteur Roux, 75015, Paris, France
| | - Hélène Duez
- Inserm, CHU Lille, Institut Pasteur de Lille, University of Lille, U1011 - EGID, 1 rue du Pr. Calmette, F-59000, Lille, France
| | - Anne Danckaert
- Experimental Neuropathology Unit, Infection and Epidemiology Department, Institut Pasteur, 25, rue du Docteur Roux, 75015, Paris, France. .,UTechS PBI (Imagopole)-Citech, Institut Pasteur, 25, rue du Docteur Roux, 75015, Paris, France.
| |
Collapse
|
16
|
Wefers J, van Moorsel D, Hansen J, Connell NJ, Havekes B, Hoeks J, van Marken Lichtenbelt WD, Duez H, Phielix E, Kalsbeek A, Boekschoten MV, Hooiveld GJ, Hesselink MKC, Kersten S, Staels B, Scheer FAJL, Schrauwen P. Circadian misalignment induces fatty acid metabolism gene profiles and compromises insulin sensitivity in human skeletal muscle. Proc Natl Acad Sci U S A 2018; 115:7789-7794. [PMID: 29987027 PMCID: PMC6065021 DOI: 10.1073/pnas.1722295115] [Citation(s) in RCA: 119] [Impact Index Per Article: 19.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Circadian misalignment, such as in shift work, has been associated with obesity and type 2 diabetes. However, direct effects of circadian misalignment on skeletal muscle insulin sensitivity and the muscle molecular circadian clock have never been studied in humans. Here, we investigated insulin sensitivity and muscle metabolism in 14 healthy young lean men [age 22.4 ± 2.8 years; body mass index (BMI) 22.3 ± 2.1 kg/m2 (mean ± SD)] after a 3-d control protocol and a 3.5-d misalignment protocol induced by a 12-h rapid shift of the behavioral cycle. We show that short-term circadian misalignment results in a significant decrease in muscle insulin sensitivity due to a reduced skeletal muscle nonoxidative glucose disposal (rate of disappearance: 23.7 ± 2.4 vs. 18.4 ± 1.4 mg/kg per minute; control vs. misalignment; P = 0.024). Fasting glucose and free fatty acid levels as well as sleeping metabolic rate were higher during circadian misalignment. Molecular analysis of skeletal muscle biopsies revealed that the molecular circadian clock was not aligned to the inverted behavioral cycle, and transcriptome analysis revealed the human PPAR pathway as a key player in the disturbed energy metabolism upon circadian misalignment. Our findings may provide a mechanism underlying the increased risk of type 2 diabetes among shift workers.
Collapse
Affiliation(s)
- Jakob Wefers
- Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands
| | - Dirk van Moorsel
- Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands
- Division of Endocrinology, Department of Internal Medicine, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands
| | - Jan Hansen
- Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands
| | - Niels J Connell
- Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands
| | - Bas Havekes
- Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands
- Division of Endocrinology, Department of Internal Medicine, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands
| | - Joris Hoeks
- Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands
| | - Wouter D van Marken Lichtenbelt
- Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands
| | - Hélène Duez
- Université de Lille-European Genomic Institute for Diabetes, Centre Hospitalier Universitaire Lille, Institut Pasteur de Lille, Inserm UMR 1011, 59019 Lille, France
| | - Esther Phielix
- Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands
| | - Andries Kalsbeek
- Hypothalamic Integration Mechanisms, Netherlands Institute for Neuroscience, 1105 BA Amsterdam, The Netherlands
| | - Mark V Boekschoten
- Nutrition, Metabolism and Genomics Group, Division of Human Nutrition, Wageningen University, 6700 EV Wageningen, The Netherlands
| | - Guido J Hooiveld
- Nutrition, Metabolism and Genomics Group, Division of Human Nutrition, Wageningen University, 6700 EV Wageningen, The Netherlands
| | - Matthijs K C Hesselink
- Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands
| | - Sander Kersten
- Nutrition, Metabolism and Genomics Group, Division of Human Nutrition, Wageningen University, 6700 EV Wageningen, The Netherlands
| | - Bart Staels
- Université de Lille-European Genomic Institute for Diabetes, Centre Hospitalier Universitaire Lille, Institut Pasteur de Lille, Inserm UMR 1011, 59019 Lille, France
| | - Frank A J L Scheer
- Medical Chronobiology Program, Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA 02115
- Division of Sleep Medicine, Harvard Medical School, Boston, MA 02115
| | - Patrick Schrauwen
- Department of Nutrition and Movement Sciences, School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands;
| |
Collapse
|
17
|
Lancel S, Hesselink MK, Woldt E, Rouillé Y, Dorchies E, Delhaye S, Duhem C, Thorel Q, Mayeuf-Louchart A, Pourcet B, Montel V, Schaart G, Beton N, Picquet F, Briand O, Salles JP, Duez H, Schrauwen P, Bastide B, Bailleul B, Staels B, Sebti Y. Endospanin-2 enhances skeletal muscle energy metabolism and running endurance capacity. JCI Insight 2018; 3:98081. [PMID: 29720572 DOI: 10.1172/jci.insight.98081] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Accepted: 03/28/2018] [Indexed: 11/17/2022] Open
Abstract
Metabolic stresses such as dietary energy restriction or physical activity exert beneficial metabolic effects. In the liver, endospanin-1 and endospanin-2 cooperatively modulate calorie restriction-mediated (CR-mediated) liver adaptations by controlling growth hormone sensitivity. Since we found CR to induce endospanin protein expression in skeletal muscle, we investigated their role in this tissue. In vivo and in vitro endospanin-2 triggers ERK phosphorylation in skeletal muscle through an autophagy-dependent pathway. Furthermore, endospanin-2, but not endospanin-1, overexpression decreases muscle mitochondrial ROS production, induces fast-to-slow fiber-type switch, increases skeletal muscle glycogen content, and improves glucose homeostasis, ultimately promoting running endurance capacity. In line, endospanin-2-/- mice display higher lipid peroxidation levels, increased mitochondrial ROS production under mitochondrial stress, decreased ERK phosphorylation, and reduced endurance capacity. In conclusion, our results identify endospanin-2 as a potentially novel player in skeletal muscle metabolism, plasticity, and function.
Collapse
Affiliation(s)
- Steve Lancel
- Université de Lille, U1011 - EGID, F-59000 Lille, France.,Inserm, U1011, F-59000 Lille, France.,CHU Lille, F-59000 Lille, France.,Institut Pasteur de Lille, F-59000 Lille, France
| | - Matthijs Kc Hesselink
- School for Nutrition, Toxicology and Metabolism, Deptartments of Human Biology and Human Movement Sciences, Maastricht University Medical Center, NL-6200 MD Maastricht, the Netherlands
| | - Estelle Woldt
- Université de Lille, U1011 - EGID, F-59000 Lille, France.,Inserm, U1011, F-59000 Lille, France.,CHU Lille, F-59000 Lille, France.,Institut Pasteur de Lille, F-59000 Lille, France
| | - Yves Rouillé
- Center of Infection and Immunity of Lille (CIIL), Inserm, U1019, CNRS UMR-8204, Institut Pasteur de Lille, Université de Lille, France
| | - Emilie Dorchies
- Université de Lille, U1011 - EGID, F-59000 Lille, France.,Inserm, U1011, F-59000 Lille, France.,CHU Lille, F-59000 Lille, France.,Institut Pasteur de Lille, F-59000 Lille, France
| | - Stephane Delhaye
- Université de Lille, U1011 - EGID, F-59000 Lille, France.,Inserm, U1011, F-59000 Lille, France.,CHU Lille, F-59000 Lille, France.,Institut Pasteur de Lille, F-59000 Lille, France
| | - Christian Duhem
- Université de Lille, U1011 - EGID, F-59000 Lille, France.,Inserm, U1011, F-59000 Lille, France.,CHU Lille, F-59000 Lille, France.,Institut Pasteur de Lille, F-59000 Lille, France
| | - Quentin Thorel
- Université de Lille, U1011 - EGID, F-59000 Lille, France.,Inserm, U1011, F-59000 Lille, France.,CHU Lille, F-59000 Lille, France.,Institut Pasteur de Lille, F-59000 Lille, France
| | - Alicia Mayeuf-Louchart
- Université de Lille, U1011 - EGID, F-59000 Lille, France.,Inserm, U1011, F-59000 Lille, France.,CHU Lille, F-59000 Lille, France.,Institut Pasteur de Lille, F-59000 Lille, France
| | - Benoit Pourcet
- Université de Lille, U1011 - EGID, F-59000 Lille, France.,Inserm, U1011, F-59000 Lille, France.,CHU Lille, F-59000 Lille, France.,Institut Pasteur de Lille, F-59000 Lille, France
| | - Valérie Montel
- URePSS, Université de Lille, EA 7369, F-59650 Villeneuve d'Ascq, France
| | - Gert Schaart
- School for Nutrition, Toxicology and Metabolism, Deptartments of Human Biology and Human Movement Sciences, Maastricht University Medical Center, NL-6200 MD Maastricht, the Netherlands
| | - Nicolas Beton
- INSERM UMR1043 (CPTP), Université de Toulouse, Paul Sabatier, Hôpital des Enfants, CHU de Toulouse, Toulouse, France
| | - Florence Picquet
- URePSS, Université de Lille, EA 7369, F-59650 Villeneuve d'Ascq, France
| | - Olivier Briand
- Université de Lille, U1011 - EGID, F-59000 Lille, France.,Inserm, U1011, F-59000 Lille, France.,CHU Lille, F-59000 Lille, France.,Institut Pasteur de Lille, F-59000 Lille, France
| | - Jean Pierre Salles
- INSERM UMR1043 (CPTP), Université de Toulouse, Paul Sabatier, Hôpital des Enfants, CHU de Toulouse, Toulouse, France
| | - Hélène Duez
- Université de Lille, U1011 - EGID, F-59000 Lille, France.,Inserm, U1011, F-59000 Lille, France.,CHU Lille, F-59000 Lille, France.,Institut Pasteur de Lille, F-59000 Lille, France
| | - Patrick Schrauwen
- School for Nutrition, Toxicology and Metabolism, Deptartments of Human Biology and Human Movement Sciences, Maastricht University Medical Center, NL-6200 MD Maastricht, the Netherlands
| | - Bruno Bastide
- URePSS, Université de Lille, EA 7369, F-59650 Villeneuve d'Ascq, France
| | - Bernard Bailleul
- Université de Lille, U1011 - EGID, F-59000 Lille, France.,Inserm, U1011, F-59000 Lille, France.,CHU Lille, F-59000 Lille, France.,Institut Pasteur de Lille, F-59000 Lille, France
| | - Bart Staels
- Université de Lille, U1011 - EGID, F-59000 Lille, France.,Inserm, U1011, F-59000 Lille, France.,CHU Lille, F-59000 Lille, France.,Institut Pasteur de Lille, F-59000 Lille, France
| | - Yasmine Sebti
- Université de Lille, U1011 - EGID, F-59000 Lille, France.,Inserm, U1011, F-59000 Lille, France.,CHU Lille, F-59000 Lille, France.,Institut Pasteur de Lille, F-59000 Lille, France
| |
Collapse
|
18
|
Pourcet B, Zecchin M, Ferri L, Beauchamp J, Sitaula S, Billon C, Delhaye S, Vanhoutte J, Mayeuf-Louchart A, Thorel Q, Haas J, Eeckhoute J, Dombrowicz D, Duhem C, Boulinguiez A, Lancel S, Sebti Y, Burris T, Staels B, Duez H. Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice. Gastroenterology 2018; 154:1449-1464.e20. [PMID: 29277561 PMCID: PMC5892845 DOI: 10.1053/j.gastro.2017.12.019] [Citation(s) in RCA: 137] [Impact Index Per Article: 22.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/08/2016] [Revised: 12/15/2017] [Accepted: 12/19/2017] [Indexed: 12/02/2022]
Abstract
BACKGROUND & AIMS The innate immune system responds not only to bacterial signals, but also to non-infectious danger-associated molecular patterns that activate the NLRP3 inflammasome complex after tissue injury. Immune functions vary over the course of the day, but it is not clear whether these changes affect the activity of the NLRP3 inflammasome. We investigated whether the core clock component nuclear receptor subfamily 1 group D member 1 (NR1D1, also called Rev-erbα) regulates expression, activity of the NLRP3 inflammasome, and its signaling pathway. METHODS We collected naïve peritoneal macrophages and plasma, at multiple times of day, from Nr1d1-/- mice and their Nr1d1+/+ littermates (controls) and analyzed expression NLRP3, interleukin 1β (IL1B, in plasma), and IL18 (in plasma). We also collected bone marrow-derived primary macrophages from these mice. Levels of NR1D1 were knocked down with small hairpin RNAs in human primary macrophages. Bone marrow-derived primary macrophages from mice and human primary macrophages were incubated with lipopolysaccharide (LPS) to induce expression of NLRP3, IL1B, and IL18; cells were incubated with LPS and adenosine triphosphate to activate the NLRP3 complex. We analyzed caspase 1 activity and cytokine secretion. NR1D1 was activated in primary mouse and human macrophages by incubation with SR9009; some of the cells were also incubated with an NLRP3 inhibitor or inhibitors of caspase 1. Nr1d1-/- mice and control mice were given intraperitoneal injections of LPS to induce peritoneal inflammation; plasma samples were isolated and levels of cytokines were measured. Nr1d1-/- mice, control mice, and control mice given injections of SR9009 were given LPS and D-galactosamine to induce fulminant hepatitis and MCC950 to specifically inhibit NLRP3; plasma was collected to measure cytokines and a marker of liver failure (alanine aminotransferase); liver tissues were collected and analyzed by quantitative polymerase chain reaction, immunohistochemistry, and flow cytometry. RESULTS In peritoneal macrophages, expression of NLRP3 and activation of its complex varied with time of day (circadian rhythm)-this regulation required NR1D1. Primary macrophages from Nr1d1-/- mice and human macrophages with knockdown of NR1D1 had altered expression patterns of NLRP3, compared to macrophages that expressed NR1D1, and altered patterns of IL1B and 1L18 production. Mice with disruption of Nr1d1 developed more-severe acute peritoneal inflammation and fulminant hepatitis than control mice. Incubation of macrophage with the NR1D1 activator SR9009 reduced expression of NLRP3 and secretion of cytokines. Mice given SR9009 developed less-severe liver failure and had longer survival times than mice given saline (control). CONCLUSIONS In studies of Nr1d1-/- mice and human macrophages with pharmacologic activation of NR1D1, we found NR1D1 to regulate the timing of NLRP3 expression and production of inflammatory cytokines by macrophages. Activation of NR1D1 reduced the severity of peritoneal inflammation and fulminant hepatitis in mice.
Collapse
Affiliation(s)
- B Pourcet
- European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Univ. Lille, F-59000 Lille, France; INSERM UMR 1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59000 Lille, France
| | - M Zecchin
- European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Univ. Lille, F-59000 Lille, France; INSERM UMR 1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59000 Lille, France
| | - L Ferri
- European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Univ. Lille, F-59000 Lille, France; INSERM UMR 1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59000 Lille, France
| | - J Beauchamp
- European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Univ. Lille, F-59000 Lille, France; INSERM UMR 1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59000 Lille, France
| | - S Sitaula
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO, USA. The Scripps Research Institute, Jupiter, FL, USA
| | - C Billon
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO, USA. The Scripps Research Institute, Jupiter, FL, USA
| | - S Delhaye
- European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Univ. Lille, F-59000 Lille, France; INSERM UMR 1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59000 Lille, France
| | - J Vanhoutte
- European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Univ. Lille, F-59000 Lille, France; INSERM UMR 1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59000 Lille, France
| | - A Mayeuf-Louchart
- European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Univ. Lille, F-59000 Lille, France; INSERM UMR 1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59000 Lille, France
| | - Q Thorel
- European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Univ. Lille, F-59000 Lille, France; INSERM UMR 1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59000 Lille, France
| | - J Haas
- European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Univ. Lille, F-59000 Lille, France; INSERM UMR 1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59000 Lille, France
| | - J Eeckhoute
- European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Univ. Lille, F-59000 Lille, France; INSERM UMR 1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59000 Lille, France
| | - D Dombrowicz
- European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Univ. Lille, F-59000 Lille, France; INSERM UMR 1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59000 Lille, France
| | - C Duhem
- European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Univ. Lille, F-59000 Lille, France; INSERM UMR 1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59000 Lille, France
| | - A Boulinguiez
- European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Univ. Lille, F-59000 Lille, France; INSERM UMR 1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59000 Lille, France
| | - S Lancel
- European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Univ. Lille, F-59000 Lille, France; INSERM UMR 1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59000 Lille, France
| | - Y Sebti
- European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Univ. Lille, F-59000 Lille, France; INSERM UMR 1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59000 Lille, France
| | - T Burris
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO, USA. The Scripps Research Institute, Jupiter, FL, USA
| | - B Staels
- European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Univ. Lille, F-59000 Lille, France; INSERM UMR 1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59000 Lille, France
| | - H Duez
- European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Univ. Lille, F-59000 Lille, France; INSERM UMR 1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59000 Lille, France,Correspondence should be addressed to Hélène Duez, UMR1011, Institut Pasteur de Lille, 1 rue Calmette, F-59019 Lille, France. Tel: +33(0)3 2087 7793,
| |
Collapse
|
19
|
Montaigne D, Marechal X, Modine T, Coisne A, Mouton S, Fayad G, Ninni S, Klein C, Ortmans S, Seunes C, Potelle C, Berthier A, Gheeraert C, Piveteau C, Deprez R, Eeckhoute J, Duez H, Lacroix D, Deprez B, Jegou B, Koussa M, Edme JL, Lefebvre P, Staels B. Daytime variation of perioperative myocardial injury in cardiac surgery and its prevention by Rev-Erbα antagonism: a single-centre propensity-matched cohort study and a randomised study. Lancet 2018; 391:59-69. [PMID: 29107324 DOI: 10.1016/s0140-6736(17)32132-3] [Citation(s) in RCA: 205] [Impact Index Per Article: 34.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Revised: 07/05/2017] [Accepted: 07/13/2017] [Indexed: 02/07/2023]
Abstract
BACKGROUND On-pump cardiac surgery provokes a predictable perioperative myocardial ischaemia-reperfusion injury which is associated with poor clinical outcomes. We determined the occurrence of time-of-the-day variation in perioperative myocardial injury in patients undergoing aortic valve replacement and its molecular mechanisms. METHODS We studied the incidence of major adverse cardiac events in a prospective observational single-centre cohort study of patients with severe aortic stenosis and preserved left ventricular ejection fraction (>50%) who were referred to our cardiovascular surgery department at Lille University Hospital (Lille, France) for aortic valve replacement and underwent surgery in the morning or afternoon. Patients were matched into pairs by propensity score. We also did a randomised study, in which we evaluated perioperative myocardial injury and myocardial samples of patients randomly assigned (1:1) via permuted block randomisation (block size of eight) to undergo isolated aortic valve replacement surgery either in the morning or afternoon. We also evaluated human and rodent myocardium in ex-vivo hypoxia-reoxygenation models and did a transcriptomic analysis in myocardial samples from the randomised patients to identify the signalling pathway(s) involved. The primary objective of the study was to assess whether myocardial tolerance of ischaemia-reperfusion differed depending on the timing of aortic valve replacement surgery (morning vs afternoon), as measured by the occurrence of major adverse cardiovascular events (cardiovascular death, myocardial infarction, and admission to hospital for acute heart failure). The randomised study is registered with ClinicalTrials.gov, number NCT02812901. FINDINGS In the cohort study (n=596 patients in matched pairs who underwent either morning surgery [n=298] or afternoon surgery [n=298]), during the 500 days following aortic valve replacement, the incidence of major adverse cardiac events was lower in the afternoon surgery group than in the morning group: hazard ratio 0·50 (95% CI 0·32-0·77; p=0·0021). In the randomised study, 88 patients were randomly assigned to undergo surgery in the morning (n=44) or afternoon (n=44); perioperative myocardial injury assessed with the geometric mean of perioperative cardiac troponin T release was significantly lower in the afternoon group than in the morning group (estimated ratio of geometric means for afternoon to morning of 0·79 [95% CI 0·68-0·93; p=0·0045]). Ex-vivo analysis of human myocardium revealed an intrinsic morning-afternoon variation in hypoxia-reoxygenation tolerance, concomitant with transcriptional alterations in circadian gene expression with the nuclear receptor Rev-Erbα being highest in the morning. In a mouse Langendorff model of hypoxia-reoxygenation myocardial injury, Rev-Erbα gene deletion or antagonist treatment reduced injury at the time of sleep-to-wake transition, through an increase in the expression of the ischaemia-reperfusion injury modulator CDKN1a/p21. INTERPRETATION Perioperative myocardial injury is transcriptionally orchestrated by the circadian clock in patients undergoing aortic valve replacement, and Rev-Erbα antagonism seems to be a pharmacological strategy for cardioprotection. Afternoon surgery might provide perioperative myocardial protection and lead to improved patient outcomes compared with morning surgery. FUNDING Fondation de France, Fédération Française de Cardiologie, EU-FP7-Eurhythdia, Agence Nationale pour la Recherche ANR-10-LABX-46, and CPER-Centre Transdisciplinaire de Recherche sur la Longévité.
Collapse
Affiliation(s)
- David Montaigne
- University of Lille, EGID, Lille, France; Inserm, U1011, Lille, France; University Hospital CHU Lille, Lille, France; Institut Pasteur de Lille, Lille, France.
| | - Xavier Marechal
- University of Lille, EGID, Lille, France; Inserm, U1011, Lille, France; Institut Pasteur de Lille, Lille, France
| | | | - Augustin Coisne
- University of Lille, EGID, Lille, France; Inserm, U1011, Lille, France; University Hospital CHU Lille, Lille, France; Institut Pasteur de Lille, Lille, France
| | - Stéphanie Mouton
- University of Lille, EGID, Lille, France; Inserm, U1011, Lille, France; University Hospital CHU Lille, Lille, France; Institut Pasteur de Lille, Lille, France
| | | | - Sandro Ninni
- University of Lille, EGID, Lille, France; Inserm, U1011, Lille, France; University Hospital CHU Lille, Lille, France; Institut Pasteur de Lille, Lille, France
| | - Cédric Klein
- University of Lille, EGID, Lille, France; Inserm, U1011, Lille, France; University Hospital CHU Lille, Lille, France; Institut Pasteur de Lille, Lille, France
| | - Staniel Ortmans
- University of Lille, EGID, Lille, France; Inserm, U1011, Lille, France; University Hospital CHU Lille, Lille, France; Institut Pasteur de Lille, Lille, France
| | - Claire Seunes
- University of Lille, EGID, Lille, France; Inserm, U1011, Lille, France; University Hospital CHU Lille, Lille, France; Institut Pasteur de Lille, Lille, France
| | - Charlotte Potelle
- University of Lille, EGID, Lille, France; University Hospital CHU Lille, Lille, France
| | - Alexandre Berthier
- University of Lille, EGID, Lille, France; Inserm, U1011, Lille, France; Institut Pasteur de Lille, Lille, France
| | - Celine Gheeraert
- University of Lille, EGID, Lille, France; Inserm, U1011, Lille, France; Institut Pasteur de Lille, Lille, France
| | - Catherine Piveteau
- University of Lille, EGID, Lille, France; Institut Pasteur de Lille, Lille, France; Inserm, U1177, Lille, France
| | - Rebecca Deprez
- University of Lille, EGID, Lille, France; Institut Pasteur de Lille, Lille, France; Inserm, U1177, Lille, France
| | - Jérome Eeckhoute
- University of Lille, EGID, Lille, France; Inserm, U1011, Lille, France; Institut Pasteur de Lille, Lille, France
| | - Hélène Duez
- University of Lille, EGID, Lille, France; Inserm, U1011, Lille, France; Institut Pasteur de Lille, Lille, France
| | - Dominique Lacroix
- University of Lille, EGID, Lille, France; University Hospital CHU Lille, Lille, France
| | - Benoit Deprez
- University of Lille, EGID, Lille, France; Institut Pasteur de Lille, Lille, France; Inserm, U1177, Lille, France
| | - Bruno Jegou
- University Hospital CHU Lille, Lille, France
| | | | - Jean-Louis Edme
- University of Lille, EGID, Lille, France; University Hospital CHU Lille, Lille, France
| | - Philippe Lefebvre
- University of Lille, EGID, Lille, France; Inserm, U1011, Lille, France; Institut Pasteur de Lille, Lille, France
| | - Bart Staels
- University of Lille, EGID, Lille, France; Inserm, U1011, Lille, France; University Hospital CHU Lille, Lille, France; Institut Pasteur de Lille, Lille, France
| |
Collapse
|
20
|
Mayeuf-Louchart A, Zecchin M, Staels B, Duez H. Circadian control of metabolism and pathological consequences of clock perturbations. Biochimie 2017; 143:42-50. [DOI: 10.1016/j.biochi.2017.07.017] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2017] [Accepted: 07/31/2017] [Indexed: 01/08/2023]
|
21
|
Woller A, Duez H, Staels B, Lefranc M. A Mathematical Model of the Liver Circadian Clock Linking Feeding and Fasting Cycles to Clock Function. Cell Rep 2017; 17:1087-1097. [PMID: 27760313 DOI: 10.1016/j.celrep.2016.09.060] [Citation(s) in RCA: 61] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2016] [Revised: 07/05/2016] [Accepted: 09/18/2016] [Indexed: 12/26/2022] Open
Abstract
To maintain energy homeostasis despite variable energy supply and consumption along the diurnal cycle, the liver relies on a circadian clock synchronized to food timing. Perturbed feeding and fasting cycles have been associated with clock disruption and metabolic diseases; however, the mechanisms are unclear. To address this question, we have constructed a mathematical model of the mammalian circadian clock, incorporating the metabolic sensors SIRT1 and AMPK. The clock response to various temporal patterns of AMPK activation was simulated numerically, mimicking the effects of a normal diet, fasting, and a high-fat diet. The model reproduces the dampened clock gene expression and NAD+ rhythms reported for mice on a high-fat diet and predicts that this effect may be pharmacologically rescued by timed REV-ERB agonist administration. Our model thus identifies altered AMPK signaling as a mechanism leading to clock disruption and its associated metabolic effects and suggests a pharmacological approach to resetting the clock in obesity.
Collapse
Affiliation(s)
- Aurore Woller
- University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France; University of Lille, CNRS, UMR 8523-PhLAM-Physique des Lasers, Atomes et Molécules, 59000 Lille, France
| | - Hélène Duez
- University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France
| | - Bart Staels
- University of Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, 59000 Lille, France.
| | - Marc Lefranc
- University of Lille, CNRS, UMR 8523-PhLAM-Physique des Lasers, Atomes et Molécules, 59000 Lille, France.
| |
Collapse
|
22
|
Mayeuf-Louchart A, Thorel Q, Delhaye S, Beauchamp J, Duhem C, Danckaert A, Lancel S, Pourcet B, Woldt E, Boulinguiez A, Ferri L, Zecchin M, Staels B, Sebti Y, Duez H. Rev-erb-α regulates atrophy-related genes to control skeletal muscle mass. Sci Rep 2017; 7:14383. [PMID: 29085009 PMCID: PMC5662766 DOI: 10.1038/s41598-017-14596-2] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2017] [Accepted: 10/12/2017] [Indexed: 12/13/2022] Open
Abstract
The nuclear receptor Rev-erb-α modulates hepatic lipid and glucose metabolism, adipogenesis and thermogenesis. We have previously demonstrated that Rev-erb-α is also an important regulator of skeletal muscle mitochondrial biogenesis and function, and autophagy. As such, Rev-erb-α over-expression in skeletal muscle or its pharmacological activation improved mitochondrial respiration and enhanced exercise capacity. Here, in gain- and loss-of function studies, we show that Rev-erb-α also controls muscle mass. Rev-erb-α-deficiency in skeletal muscle leads to increased expression of the atrophy-related genes (atrogenes), associated with reduced muscle mass and decreased fiber size. By contrast, in vivo and in vitro Rev-erb-α over-expression results in reduced atrogenes expression and increased fiber size. Finally, Rev-erb-α pharmacological activation blocks dexamethasone-induced upregulation of atrogenes and muscle atrophy. This study identifies Rev-erb-α as a promising pharmacological target to preserve muscle mass.
Collapse
Affiliation(s)
- Alicia Mayeuf-Louchart
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
| | - Quentin Thorel
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
| | - Stéphane Delhaye
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
| | - Justine Beauchamp
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
| | - Christian Duhem
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
| | | | - Steve Lancel
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
| | - Benoit Pourcet
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
| | - Estelle Woldt
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
| | - Alexis Boulinguiez
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
| | - Lise Ferri
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
| | - Mathilde Zecchin
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
| | - Bart Staels
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
| | - Yasmine Sebti
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France
| | - Hélène Duez
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France.
| |
Collapse
|
23
|
Zecchin M, Pourcet B, Ferri L, Vanhoutte J, Delhaye S, Staels B, Duez H. Role of the nuclear receptor Rev-erb-alpha in the development of vascular calcification. Atherosclerosis 2017. [DOI: 10.1016/j.atherosclerosis.2017.06.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
24
|
Boulinguiez A, Staels B, Duez H, Lancel S. Mitochondria and endoplasmic reticulum: Targets for a better insulin sensitivity in skeletal muscle? Biochim Biophys Acta Mol Cell Biol Lipids 2017; 1862:901-916. [PMID: 28529179 DOI: 10.1016/j.bbalip.2017.05.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 05/15/2017] [Accepted: 05/17/2017] [Indexed: 12/16/2022]
Abstract
Obesity and its associated metabolic disorders represent a major health burden, with economic and social consequences. Although adapted lifestyle and bariatric surgery are effective in reducing body weight, obesity prevalence is still rising. Obese individuals often become insulin-resistant. Obesity impacts on insulin responsive organs, such as the liver, adipose tissue and skeletal muscle, and increases the risk of cardiovascular diseases, type 2 diabetes and cancer. In this review, we discuss the effects of obesity and insulin resistance on skeletal muscle, an important organ for the control of postprandial glucose. The roles of mitochondria and the endoplasmic reticulum in insulin signaling are highlighted and potential innovative research and treatment perspectives are proposed.
Collapse
Affiliation(s)
- Alexis Boulinguiez
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France.
| | - Bart Staels
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France.
| | - Hélène Duez
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France.
| | - Steve Lancel
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000, Lille, France.
| |
Collapse
|
25
|
Abstract
In mammals, the central clock localized in the central nervous system imposes a circadian rhythmicity to all organs. This is achieved thanks to a well-conserved molecular clockwork, involving interactions between several transcription factors, whose pace is conveyed to peripheral tissues through neuronal and humoral signals. The molecular clock plays a key role in the control of numerous physiological processes and takes part in the regulation of metabolism and energy balance. Skeletal muscle is one of the peripheral organs whose function is under the control of the molecular clock. However, although skeletal muscle metabolism and performances display circadian rhythmicity, the role of the molecular clock in the skeletal muscle has remained unappreciated for years. Peripheral organs such as skeletal muscle, and the liver, among others, can be desynchronized from the central clock by external stimuli, such as feeding or exercise, which impose a new rhythm at the organism level. In this review, we discuss our current understanding of the clock in skeletal muscle circadian physiology, focusing on the control of myogenesis and skeletal muscle metabolism.
Collapse
Affiliation(s)
- A Mayeuf-Louchart
- University of Lille, U1011, EGID, F-59000, Lille, France
- INSERM, U1011, F-59000 Lille, France
- CHU Lille, F-59000, Lille, France
- Institut Pasteur de Lille, U1011, F-59000 Lille, France
| | - B Staels
- University of Lille, U1011, EGID, F-59000, Lille, France
- INSERM, U1011, F-59000 Lille, France
- CHU Lille, F-59000, Lille, France
- Institut Pasteur de Lille, U1011, F-59000 Lille, France
| | - H Duez
- University of Lille, U1011, EGID, F-59000, Lille, France
- INSERM, U1011, F-59000 Lille, France
- CHU Lille, F-59000, Lille, France
- Institut Pasteur de Lille, U1011, F-59000 Lille, France
| |
Collapse
|
26
|
Pourcet B, Zecchin M, Vanhoutte J, Delhaye S, Rommens C, Woldt E, Eeckhoute J, Staels B, Duez H. Role of the nuclear receptor Rev-erb-alpha in the development of atherosclerosis. Atherosclerosis 2015. [DOI: 10.1016/j.atherosclerosis.2015.04.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
27
|
Montaigne D, Marechal X, Coisne A, Debry N, Modine T, Fayad G, Potelle C, El Arid JM, Mouton S, Sebti Y, Duez H, Preau S, Remy-Jouet I, Zerimech F, Koussa M, Richard V, Neviere R, Edme JL, Lefebvre P, Staels B. Myocardial Contractile Dysfunction Is Associated With Impaired Mitochondrial Function and Dynamics in Type 2 Diabetic but Not in Obese Patients. Circulation 2014; 130:554-64. [DOI: 10.1161/circulationaha.113.008476] [Citation(s) in RCA: 193] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- David Montaigne
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Xavier Marechal
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Augustin Coisne
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Nicolas Debry
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Thomas Modine
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Georges Fayad
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Charlotte Potelle
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Jean-Marc El Arid
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Stéphanie Mouton
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Yasmine Sebti
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Hélène Duez
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Sébastien Preau
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Isabelle Remy-Jouet
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Farid Zerimech
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Mohamed Koussa
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Vincent Richard
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Remi Neviere
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Jean-Louis Edme
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Philippe Lefebvre
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| | - Bart Staels
- From the Department of Physiology, Faculty of Medicine Lille, Lille, France (D.M., X.M., A.C., N.D., C.P., S.M., S.P., R.N.); Service d’Explorations Fonctionnelles CardioVasculaires (D.M., A.C., S.M.), Department of Cardiovascular Surgery (T.M., G.F., J.-M.E.A., M.K.), and Biochemistry Division, Pathology and Biology Center (F.Z.), University Hospital of Lille, Lille, France; Université Lille 2, Inserm, U1011, and Institut Pasteur de Lille, Lille, France (D.M., X.M., Y.S., H.D., P.L., B.S.)
| |
Collapse
|
28
|
Oger F, Gheeraert C, Mogilenko D, Benomar Y, Molendi-Coste O, Bouchaert E, Caron S, Dombrowicz D, Pattou F, Duez H, Eeckhoute J, Staels B, Lefebvre P. Cell-specific dysregulation of microRNA expression in obese white adipose tissue. J Clin Endocrinol Metab 2014; 99:2821-33. [PMID: 24758184 DOI: 10.1210/jc.2013-4259] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT Obesity is characterized by the excessive accumulation of dysfunctional white adipose tissue (WAT), leading to a strong perturbation of metabolic regulations. However, the molecular events underlying this process are not fully understood. OBJECTIVE MicroRNAs (miRNAs) are small noncoding RNAs acting as posttranscriptional regulators of gene expression in multiple tissues and organs. However, their expression and roles in WAT cell subtypes, which include not only adipocytes but also immune, endothelial, and mesenchymal stem cells as well as preadipocytes, have not been characterized. Design/Results: By applying differential miRNome analysis, we demonstrate that the expression of several miRNAs is dysregulated in epididymal WAT from ob/ob and high-fat diet-fed mice. Adipose tissue-specific down-regulation of miR-200a and miR-200b and the up-regulation of miR-342-3p, miR-335-5p, and miR-335-3p were observed. Importantly, a similarly altered expression of miR-200a and miR-200b was observed in obese diabetic patients. Furthermore, cell fractionation of mouse adipose tissue revealed that miRNAs are differentially expressed in adipocytes and in subpopulations from the stromal vascular fraction. Finally, integration of transcriptomic data showed that bioinformatically predicted miRNA target genes rarely showed anticorrelated expression with that of targeting miRNA, in contrast to experimentally validated target genes. CONCLUSION Taken together, our data indicate that the dysregulated expression of miRNAs occurs in distinct cell types and is likely to affect cell-specific function(s) of obese WAT.
Collapse
Affiliation(s)
- Frédérik Oger
- European Genomic Institute for Diabetes (F.O., C.G., D.M., Y.B., O.M.-C., E.B., S.C., D.D., F.P., H.D., J.E., B.S., P.L.), Inserm Unité Mixte de Recherche Unité 1011 (F.O., C.G., D.M., Y.B., O.M.-C., E.B., S.C., D.D., H.D., J.E., B.S., P.L.), Université Lille 2 (F.O., C.G., D.M., Y.B., O.M.-C., E.B., S.C., D.D., F.P., H.D., J.E., B.S., P.L.), and Inserm Unité Mixte de Recherche Unité 859 (F.P.), F-59000 Lille, France; Institut Pasteur de Lille (F.O., C.G., D.M., Y.B., O.M.-C., E.B., S.C., D.D., H.D., J.E., B.S., P.L.), F-59019 Lille, France; and Centre Hospitalier Régional Universitaire de Lille (F.P.), F-59045, Lille, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Makki K, Taront S, Molendi-Coste O, Bouchaert E, Neve B, Eury E, Lobbens S, Labalette M, Duez H, Staels B, Dombrowicz D, Froguel P, Wolowczuk I. Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice. PLoS One 2014; 9:e92684. [PMID: 24710396 PMCID: PMC3977858 DOI: 10.1371/journal.pone.0092684] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2013] [Accepted: 02/25/2014] [Indexed: 12/20/2022] Open
Abstract
The “mechanistic target of rapamycin” (mTOR) is a central controller of growth, proliferation and/or motility of various cell-types ranging from adipocytes to immune cells, thereby linking metabolism and immunity. mTOR signaling is overactivated in obesity, promoting inflammation and insulin resistance. Therefore, great interest exists in the development of mTOR inhibitors as therapeutic drugs for obesity or diabetes. However, despite a plethora of studies characterizing the metabolic consequences of mTOR inhibition in rodent models, its impact on immune changes associated with the obese condition has never been questioned so far. To address this, we used a mouse model of high-fat diet (HFD)-fed mice with and without pharmacologic mTOR inhibition by rapamycin. Rapamycin was weekly administrated to HFD-fed C57BL/6 mice for 22 weeks. Metabolic effects were determined by glucose and insulin tolerance tests and by indirect calorimetry measures of energy expenditure. Inflammatory response and immune cell populations were characterized in blood, adipose tissue and liver. In parallel, the activities of both mTOR complexes (e. g. mTORC1 and mTORC2) were determined in adipose tissue, muscle and liver. We show that rapamycin-treated mice are leaner, have enhanced energy expenditure and are protected against insulin resistance. These beneficial metabolic effects of rapamycin were associated to significant changes of the inflammatory profiles of both adipose tissue and liver. Importantly, immune cells with regulatory functions such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) were increased in adipose tissue. These rapamycin-triggered metabolic and immune effects resulted from mTORC1 inhibition whilst mTORC2 activity was intact. Taken together, our results reinforce the notion that controlling immune regulatory cells in metabolic tissues is crucial to maintain a proper metabolic status and, more generally, comfort the need to search for novel pharmacological inhibitors of the mTOR signaling pathway to prevent and/or treat metabolic diseases.
Collapse
Affiliation(s)
- Kassem Makki
- Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR)8199, Lille Pasteur Institute, Lille, France
- Lille 2 University, Lille, France
- European Genomic Institute for Diabetes (EGID), Lille, France
| | - Solenne Taront
- Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR)8199, Lille Pasteur Institute, Lille, France
- Lille 2 University, Lille, France
- European Genomic Institute for Diabetes (EGID), Lille, France
| | - Olivier Molendi-Coste
- Lille 2 University, Lille, France
- European Genomic Institute for Diabetes (EGID), Lille, France
- Institut National de la Santé et de la Recherche Médicale (Inserm), UMR1011, Lille Pasteur Institute, Lille, France
| | - Emmanuel Bouchaert
- Lille 2 University, Lille, France
- European Genomic Institute for Diabetes (EGID), Lille, France
- Institut National de la Santé et de la Recherche Médicale (Inserm), UMR1011, Lille Pasteur Institute, Lille, France
| | - Bernadette Neve
- Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR)8199, Lille Pasteur Institute, Lille, France
- Lille 2 University, Lille, France
- European Genomic Institute for Diabetes (EGID), Lille, France
| | - Elodie Eury
- Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR)8199, Lille Pasteur Institute, Lille, France
- Lille 2 University, Lille, France
- European Genomic Institute for Diabetes (EGID), Lille, France
| | - Stéphane Lobbens
- Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR)8199, Lille Pasteur Institute, Lille, France
- Lille 2 University, Lille, France
- European Genomic Institute for Diabetes (EGID), Lille, France
| | - Myriam Labalette
- Lille 2 University, Lille, France
- Immunology Institute, Centre Hospitalier Régional Universitaire (CHRU) Lille and Equipe d'Accueil (EA)2686, Lille 2 University, Lille, France
| | - Hélène Duez
- Lille 2 University, Lille, France
- European Genomic Institute for Diabetes (EGID), Lille, France
- Institut National de la Santé et de la Recherche Médicale (Inserm), UMR1011, Lille Pasteur Institute, Lille, France
| | - Bart Staels
- Lille 2 University, Lille, France
- European Genomic Institute for Diabetes (EGID), Lille, France
- Institut National de la Santé et de la Recherche Médicale (Inserm), UMR1011, Lille Pasteur Institute, Lille, France
| | - David Dombrowicz
- Lille 2 University, Lille, France
- European Genomic Institute for Diabetes (EGID), Lille, France
- Institut National de la Santé et de la Recherche Médicale (Inserm), UMR1011, Lille Pasteur Institute, Lille, France
| | - Philippe Froguel
- Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR)8199, Lille Pasteur Institute, Lille, France
- Lille 2 University, Lille, France
- European Genomic Institute for Diabetes (EGID), Lille, France
- Department of Genomics of Common Disease, School of Public Health, Imperial College London, London, United Kingdom
- * E-mail: (PF); (IW)
| | - Isabelle Wolowczuk
- Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR)8199, Lille Pasteur Institute, Lille, France
- Lille 2 University, Lille, France
- European Genomic Institute for Diabetes (EGID), Lille, France
- * E-mail: (PF); (IW)
| |
Collapse
|
30
|
Duez H, Sebti Y, Staels B. Horloges circadiennes et métabolisme : intégration des signaux métaboliques et environnementaux. Med Sci (Paris) 2013; 29:772-7. [DOI: 10.1051/medsci/2013298017] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
|
31
|
Woldt E, Sebti Y, Solt LA, Duhem C, Lancel S, Eeckhoute J, Hesselink MKC, Paquet C, Delhaye S, Shin Y, Kamenecka TM, Schaart G, Lefebvre P, Nevière R, Burris TP, Schrauwen P, Staels B, Duez H. Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat Med 2013; 19:1039-46. [PMID: 23852339 PMCID: PMC3737409 DOI: 10.1038/nm.3213] [Citation(s) in RCA: 326] [Impact Index Per Article: 29.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2012] [Accepted: 04/24/2013] [Indexed: 12/12/2022]
Abstract
The nuclear receptor Rev-erb-α modulates hepatic lipid and glucose metabolism, adipogenesis and the inflammatory response in macrophages. We show here that Rev-erb-α is highly expressed in oxidative skeletal muscle and plays a role in mitochondrial biogenesis and oxidative function, in gain- and loss-of function studies. Rev-erb-α-deficiency in skeletal muscle leads to reduced mitochondrial content and oxidative function, resulting in compromised exercise capacity. This phenotype was recapitulated in isolated fibers and in muscle cells upon Rev-erbα knock-down, while Rev-erb-α over-expression increased the number of mitochondria with improved respiratory capacity. Rev-erb-α-deficiency resulted in deactivation of the Stk11–Ampk–Sirt1–Ppargc1-α signaling pathway, whereas autophagy was up-regulated, resulting in both impaired mitochondrial biogenesis and increased clearance. Muscle over-expression or pharmacological activation of Rev-erb-α increased respiration and exercise capacity. This study identifies Rev-erb-α as a pharmacological target which improves muscle oxidative function by modulating gene networks controlling mitochondrial number and function.
Collapse
|
32
|
Duez H, Cariou B, Staels B. DPP-4 inhibitors in the treatment of type 2 diabetes. Biochem Pharmacol 2011; 83:823-32. [PMID: 22172989 DOI: 10.1016/j.bcp.2011.11.028] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2011] [Revised: 11/29/2011] [Accepted: 11/29/2011] [Indexed: 12/25/2022]
Abstract
Although being a primary objective in the management of type 2 diabetes, optimal glycaemic control is difficult to achieve and usually not maintained over time. Type 2 diabetes is a complex pathology, comprising altered insulin sensitivity and impaired insulin secretion. Recent advances in the understanding of the physiological functions of incretins and their degrading enzyme dipeptidyl-peptidase (DPP)-4 have led to the 'discovery' of a new class of oral anti-diabetic drugs. Several DPP-4 inhibitors (or gliptins) with different chemical structures are now available. These agents inhibit the degradation of the incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) and hence potentiate glucose-dependent insulin secretion. DPP-4 inhibitors inhibit DPP-4 activity by almost 100% in vitro, maintaining a ≥ 80% inhibition throughout the treatment period in vivo, thus prolonging GLP-1 half-life, and significantly reducing HbA1c generally by -0.7 to 0.8% as well as fasting and post-prandial glycaemia. They are well-tolerated with no weight gain and few adverse effects, and, of particular interest, no increase in hypoglycaemic episodes. Although different by their chemical structure and pharmacokinetic properties, the DPP4 inhibitors currently available have proven similar glucose lowering efficacy.
Collapse
Affiliation(s)
- Hélène Duez
- Univ Lille Nord de France, F-59000 Lille, France
| | | | | |
Collapse
|
33
|
|
34
|
Bauge E, Comte C, Duhem C, Vanhoutte J, Staels B, Duez H. 446 ATHEROSCLEROTIC LESION REMODELLING IN REV-ERBα-DEFICIENT MICE. ATHEROSCLEROSIS SUPP 2011. [DOI: 10.1016/s1567-5688(11)70447-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
35
|
Abstract
Many behavioral and physiological processes, including locomotor activity, blood pressure, body temperature, sleep (fasting)/wake (feeding) cycles, and metabolic regulation display diurnal rhythms. The biological clock ensures proper metabolic alignment of energy substrate availability and processing. Studies in animals and humans highlight a strong link between circadian disorders and altered metabolic responses and cardiovascular events. Shift work, for instance, increases the risk to develop metabolic abnormalities resembling the metabolic syndrome. Nuclear receptors have long been known as metabolic regulators. Several of them (ie, Rev-erbalpha, RORalpha, and peroxisome proliferation-activated receptors) are subjected to circadian variations and are integral components of molecular clock machinery. In turn, these nuclear receptors regulate downstream target genes in a circadian manner, acting to properly gate metabolic events to the appropriate circadian time window.
Collapse
Affiliation(s)
- Hélène Duez
- Department of Nuclear Receptors, Cardiovascular Disease and Diabetes, University of Lille Nord de France, Inserm, UDSL, and Institut Pasteur de Lille, Lille, France.
| | | |
Collapse
|
36
|
Prawitt J, Abdelkarim M, Dumont J, Duez H, Stroeve J, van Dijk T, Bouchaert E, Kuipers F, Cariou B, Caron S, Staels B. W40 FXR-DEFICIENCY IMPROVES GLUCOSE AND ENERGY HOMEOSTASIS IN GENETIC OBESITY. ATHEROSCLEROSIS SUPP 2010. [DOI: 10.1016/s1567-5688(10)70041-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Abstract
The endogenous circadian clock ensures daily rhythms in diverse behavioral and physiological processes, including locomotor activity and sleep/wake cycles, but also food intake patterns. Circadian rhythms are generated by an internal clock system, which synchronizes these daily variations to the day/night alternance. In addition, circadian oscillations may be reset by the time of food availability in peripheral metabolic organs. Circadian rhythms are seen in many metabolic pathways (glucose and lipid metabolism, etc.) and endocrine secretions (insulin, etc.). As a consequence, misalignment of the internal timing system vs. environmental zeitgebers (light, for instance), as experienced during jetlag or shift work, may result in disruption of physiological cycles of fuel utilization or energy storage. A large body of evidence from both human and animal studies now points to a relationship between circadian disorders and altered metabolic response, suggesting that circadian and metabolic regulatory networks are tightly connected. After a review of the current understanding of the molecular circadian core clock, we will discuss the hypothesis that clock genes themselves link the core molecular clock and metabolic regulatory networks. We propose that the nuclear receptor and core clock component Rev-erb-alpha behaves as a gatekeeper to timely coordinate the circadian metabolic response.
Collapse
Affiliation(s)
- Hélène Duez
- University Lille Nord de France, Lille, France.
| | | |
Collapse
|
38
|
Duez H, Duhem C, Laitinen S, Patole PS, Abdelkarim M, Bois-Joyeux B, Danan JL, Staels B. Inhibition of adipocyte differentiation by RORalpha. FEBS Lett 2009; 583:2031-6. [PMID: 19450581 DOI: 10.1016/j.febslet.2009.05.019] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2009] [Revised: 04/27/2009] [Accepted: 05/08/2009] [Indexed: 01/27/2023]
Abstract
Here we show that gene expression of the nuclear receptor RORalpha is induced during adipogenesis, with RORalpha4 being the most abundantly expressed isoform in human and murine adipose tissue. Over-expression of RORalpha4 in 3T3-L1 cells impairs adipogenesis as shown by the decreased expression of adipogenic markers and lipid accumulation, accompanied by decreased free fatty acid and glucose uptake. By contrast, mouse embryonic fibroblasts from staggerer mice, which carry a mutation in the RORalpha gene, differentiate more efficiently into mature adipocytes compared to wild-type cells, a phenotype which is reversed by ectopic RORalpha4 restoration.
Collapse
MESH Headings
- 3T3-L1 Cells
- Adipocytes/cytology
- Adipocytes/metabolism
- Adipogenesis/genetics
- Adipogenesis/physiology
- Adult
- Animals
- Cell Differentiation/genetics
- Cell Differentiation/physiology
- Fatty Acids, Nonesterified/metabolism
- Gene Expression
- Glucose/metabolism
- Humans
- In Vitro Techniques
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Neurologic Mutants
- Nuclear Receptor Subfamily 1, Group F, Member 1
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Receptors, Cytoplasmic and Nuclear/deficiency
- Receptors, Cytoplasmic and Nuclear/genetics
- Receptors, Cytoplasmic and Nuclear/metabolism
- Recombinant Proteins/genetics
- Recombinant Proteins/metabolism
- Trans-Activators/deficiency
- Trans-Activators/genetics
- Trans-Activators/metabolism
Collapse
Affiliation(s)
- Hélène Duez
- Institut Pasteur de Lille, Département d'Athérosclérose, Lille F-59019, France
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Duez H, Smith AC, Xiao C, Giacca A, Szeto L, Drucker DJ, Lewis GF. Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice. Endocrinology 2009; 150:56-62. [PMID: 18801896 DOI: 10.1210/en.2008-1137] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Pharmacological approaches that enhance incretin action for the treatment of type 2 diabetes mellitus have recently been developed, i.e. injectable glucagon-like peptide-1 receptor (GLP-1R) agonists with prolonged plasma half-lives and orally available inhibitors of dipeptidyl peptidase (DPP)-4, the main enzyme responsible for the rapid degradation of circulating glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. The mechanism(s) underlying the glucose-lowering effect of these two pharmacotherapies differs and is not yet fully understood. Here we investigated whether acute GLP-1R activation (exendin-4) or DPP-4 inhibition (des-F-sitagliptin) modulates insulin action in mice using a hyperinsulinemic euglycemic clamp. A single iv bolus of des-F-sitagliptin (11 mg/kg) was administered to mice 15 min after the start of the clamp, and its effect was compared with a 50-ng bolus of exendin-4 or the same volume of saline. Despite matched levels of plasma glucose and insulin, within 15 min the glucose infusion rate required to maintain euglycemia was significantly greater after des-F-sitagliptin compared with saline or exendin-4. This difference was entirely due to enhancement of insulin-mediated suppression of endogenous glucose production by des-F-sitagliptin, with no difference in glucose disposal rate. These findings illustrate that DPP-4 inhibition modulates glucose homeostasis through pathways distinct from those used by GLP-1R agonists in mice.
Collapse
Affiliation(s)
- Hélène Duez
- Department of Medicine and Physiology, Division of Endocrinology and Metabolism, University of Toronto,Toronto, Ontario, Canada
| | | | | | | | | | | | | |
Collapse
|
40
|
Duez H, Pavlic M, Lewis GF. Mechanism of intestinal lipoprotein overproduction in insulin resistant humans. ATHEROSCLEROSIS SUPP 2008; 9:33-8. [DOI: 10.1016/j.atherosclerosissup.2008.05.013] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2008] [Revised: 02/25/2008] [Accepted: 05/13/2008] [Indexed: 10/21/2022]
|
41
|
Duez H, van der Veen JN, Duhem C, Pourcet B, Touvier T, Fontaine C, Derudas B, Baugé E, Havinga R, Bloks VW, Wolters H, van der Sluijs FH, Vennström B, Kuipers F, Staels B. Regulation of bile acid synthesis by the nuclear receptor Rev-erbalpha. Gastroenterology 2008; 135:689-98. [PMID: 18565334 DOI: 10.1053/j.gastro.2008.05.035] [Citation(s) in RCA: 167] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2007] [Revised: 04/18/2008] [Accepted: 05/08/2008] [Indexed: 01/04/2023]
Abstract
BACKGROUND & AIMS Conversion into bile acids represents an important route to remove excess cholesterol from the body. Rev-erbalpha is a nuclear receptor that participates as one of the clock genes in the control of circadian rhythmicity and plays a regulatory role in lipid metabolism and adipogenesis. Here, we investigate a potential role for Rev-erbalpha in the control of bile acid metabolism via the regulation of the neutral bile acid synthesis pathway. METHODS Bile acid synthesis and CYP7A1 gene expression were studied in vitro and in vivo in mice deficient for or over expressing Rev-erbalpha. RESULTS Rev-erbalpha-deficient mice display a lower synthesis rate and an impaired excretion of bile acids into the bile and feces. Expression of CYP7A1, the rate-limiting enzyme of the neutral pathway, is decreased in livers of Rev-erbalpha-deficient mice, whereas adenovirus-mediated hepatic Rev-erbalpha overexpression induces its expression. Moreover, bile acid feeding resulted in a more pronounced suppression of hepatic CYP7A1 expression in Rev-erbalpha-deficient mice. Hepatic expression of E4BP4 and the orphan nuclear receptor small heterodimer partner (SHP), both negative regulators of CYP7A1 expression, is increased in Rev-erbalpha-deficient mice. Promoter analysis and chromatin immunoprecipitation experiments demonstrated that SHP and E4BP4 are direct Rev-erbalpha target genes. Finally, the circadian rhythms of liver CYP7A1, SHP, and E4BP4 messenger RNA levels were perturbed in Rev-erbalpha-deficient mice. CONCLUSIONS These data identify a role for Rev-erbalpha in the regulatory loop of bile acid synthesis, likely acting by regulating both hepatic SHP and E4BP4 expression.
Collapse
Affiliation(s)
- Hélène Duez
- Institut Pasteur de Lille, Département d'Athérosclérose, Lille, France; Inserm, U545, Lille, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Pavlic M, Valéro R, Duez H, Xiao C, Szeto L, Patterson BW, Lewis GF. Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans. Arterioscler Thromb Vasc Biol 2008; 28:1660-5. [PMID: 18556566 DOI: 10.1161/atvbaha.108.169383] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Insulin resistant states are associated with increased fatty acid flux to liver and intestine, which stimulates the production of triglyceride-rich lipoproteins (TRL). ApoC-III production and plasma and TRL concentrations are increased in insulin resistance and may contribute to the hypertriglyceridemia of these conditions. The mechanism underlying that increase is not known, but because apoC-III and VLDL production are closely linked we hypothesized that FFAs may stimulate TRL apoC-III production. METHODS AND RESULTS We used Intralipid/heparin (IH) to raise plasma FFA in 12 healthy men in the fed state, and stable isotopes to examine apoC-III metabolism. TRL apoC-III concentration was significantly higher in the IH study, and this increase was associated with higher production (PR) and fractional catabolic rate (FCR). The increase in production was greater than in FCR (90% versus 30%, respectively), accounting for the elevated concentration. Glycerol infusion had no effect on apoC-III concentration, PR, or FCR compared to saline, indicating that the effect was not attributable to glycerol released from intralipid. CONCLUSIONS These findings confirm that TRL apoC-III production is stimulated by an acute elevation of plasma FFAs, suggesting a novel regulatory pathway that may play a role in the overproduction of TRL apoC-III in insulin resistant states.
Collapse
|
43
|
Abstract
Circadian rhythms are normal variations in physiological processes that occur over the period of a day. These rhythms are essential for the organism since they allow anticipatory metabolic regulations to prepare for the up-coming feeding or rest period. Disturbances of the biological clock predispose to metabolic disorders such as dyslipidaemia, insulin resistance and obesity. Moreover, certain pathological events, such as cardiovascular accidents (myocardial infarction, stroke) occur more frequently at specific times of the day. The nuclear receptors Rev-erbalpha and RORalpha are clock components involved in the regulation of the core clock circuitry. They are also important regulators of lipid and lipoprotein metabolism, adipogenesis and vascular inflammation. Moreover, they cross-talk with several other nuclear receptors controlling energy homeostasis. Therefore, Rev-erbalpha and RORalpha may play a central role in the coordination of metabolic processes and circadian outputs.
Collapse
Affiliation(s)
- Hélène Duez
- Institut Pasteur de Lille, 1, rue Calmette, BP 245, F-59019 Lille, France
| | | |
Collapse
|
44
|
Fontaine C, Rigamonti E, Pourcet B, Duez H, Duhem C, Fruchart JC, Chinetti-Gbaguidi G, Staels B. The nuclear receptor Rev-erbalpha is a liver X receptor (LXR) target gene driving a negative feedback loop on select LXR-induced pathways in human macrophages. Mol Endocrinol 2008; 22:1797-811. [PMID: 18511497 DOI: 10.1210/me.2007-0439] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
A role of the nuclear receptor Rev-erbalpha in the regulation of transcription pathways involving other nuclear receptors is emerging. Indeed, Rev-erbalpha is a negative regulator of transcription by binding to overlapping response elements shared with various nuclear receptors, including the peroxisome proliferator-activated receptors and the retinoid-related orphan receptor alpha (RORalpha). Here, we show that Rev-erbalpha is expressed in primary human macrophages and that its expression is induced by synthetic ligands for the liver X receptors (LXRs), which control cholesterol homeostasis, inflammation, and the immune response in macrophages. LXRalpha binds to a specific response element in the human Rev-erbalpha promoter, thus inducing Rev-erbalpha transcriptional expression. Interestingly, Rev-erbalpha does not influence basal or LXR-regulated cholesterol homeostasis. However, Rev-erbalpha overexpression represses the induction of toll-like receptor (TLR)-4 by LXR agonists, whereas Rev-erbalpha silencing by short interfering RNA results in enhanced TLR-4 expression upon LXR activation. Electrophoretic mobility shift, chromatin immunoprecipitation, and transient transfection experiments demonstrate that Rev-erbalpha represses human TLR-4 promoter activity by binding as a monomer to a RevRE site overlapping with the LXR response element site in the TLR-4 promoter. These data identify Rev-erbalpha as a new LXR target gene, inhibiting LXR-induction of TLR-4 in a negative transcriptional feedback loop, but not cholesterol homeostasis gene expression.
Collapse
Affiliation(s)
- Coralie Fontaine
- Institut National de la Santé et de la Recherche Médicale, Unité 545, Institut Pasteur de Lille, 1, rue du Professeur Calmette, Boite Postale 245, Lille 59019, France
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Duez H, Lamarche B, Uffelman KD, Valéro R, Szeto L, Lemieux S, Cohn JS, Lewis GF. Dissociation between the insulin-sensitizing effect of rosiglitazone and its effect on hepatic and intestinal lipoprotein production. J Clin Endocrinol Metab 2008; 93:1722-9. [PMID: 18285418 DOI: 10.1210/jc.2007-2110] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
CONTEXT Despite its potent, well-documented insulin-sensitizing effects, rosiglitazone (RSG) does not effectively ameliorate the hypertriglyceridemia of insulin-resistant or diabetic individuals and has even been shown to slightly but significantly increase triglyceride-rich lipoproteins (TRL) in some studies. The mechanism of this effect is currently not known. OBJECTIVE We investigated the effect of RSG treatment on TRL metabolism. DESIGN This was a 12-wk, single-sequence, cross-over study of rosiglitazone vs. placebo for 6 wk. PARTICIPANTS Participants included 17 nondiabetic men with a broad range of insulin sensitivity. INTERVENTION INTERVENTION included rosiglitazone 8 mg/d vs. placebo for 6 wk. MAIN OUTCOME MEASURE TRL metabolism (concentration, production and catabolic rates) was assessed in a constant fed state with a 12-h primed constant infusion of [D3]l-leucine and multicompartmental modeling. RESULTS RSG treatment resulted in significant insulin sensitization with no change in body weight. Fasting plasma triglyceride (TG) concentration, however, was higher with RSG vs. placebo (P = 0.0006), as were fasting and fed TRL-TG, TRL-apoB-48, and TRL-apoB-100 (fed TRL-apoB-48: 0.93 +/- 0.08 vs. 0.76 +/- 0.07 mg/dl, P =0.017, and fed TRL-apoB-100: 15.57 +/- 0.90 vs. 13.71 +/- 1.27 mg/dl, P = 0.029). This small but significant increase in plasma TRL concentration was explained by a tendency for RSG to increase TRL production and reduce particle clearance, as indicated by the significantly increased production to clearance ratios for both apoB-48-containing (0.43 +/- 0.03 vs. 0.34 +/- 0.03, P = 0.048) and apoB-100-containing (7.0 +/- 0.4 vs. 6.2 +/- 0.6, P = 0.029) TRL. CONCLUSION These data indicate dissociation between the insulin-sensitizing effects of RSG and absence of anticipated reductions in production rates of apoB-100- and apoB-48-containing-TRL particles, which may explain the absence of TG lowering seen in humans treated with this agent.
Collapse
Affiliation(s)
- Hélène Duez
- Departments of Medicine and Physiology, Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Duez H, Lamarche B, Valéro R, Pavlic M, Proctor S, Xiao C, Szeto L, Patterson BW, Lewis GF. Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation 2008. [PMID: 18443237 DOI: 10.1161/circulationaha.107] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
BACKGROUND Hepatic lipoprotein production has been shown previously to be regulated by free fatty acid (FFA) flux to the liver, whereas intestinal lipoprotein production is stimulated mainly by ingested fat absorbed from the intestinal lumen. Emerging evidence indicates that intestinal lipoprotein production is increased in insulin resistance and type 2 diabetes mellitus, conditions that are associated with increased levels of circulating FFAs. Here we investigated whether short-term elevation of plasma FFAs stimulates intestinal apolipoprotein (apo) B-48- and hepatic apoB-100-containing triglyceride-rich lipoprotein (TRL) production in humans in the fed state. METHODS AND RESULTS TRL apoB-48 and apoB-100 metabolism were examined in 12 healthy men during a constant fed state. The studies were as follows, respectively: (1) Intralipid/heparin was infused intravenously immediately before and during the kinetics study to induce an approximately 3-fold difference in plasma FFA compared with the saline study; (2) saline was infused intravenously as a control. ApoB-48- and apoB-100-containing TRL production and clearance were determined with a 12-hour primed constant infusion of [D3]L-leucine and multicompartmental kinetic modeling. TRL apoB-48 production rate was 69% higher in the Intralipid/heparin study than in the saline control (5.95+/-1.13 versus 3.53+/-0.58 mg/kg per day; P=0.027), and there was no significant difference in TRL apoB-48 clearance. TRL apoB-100 concentrations were also increased (P<0.001) and TRL apoB-100 production rate was 35% higher in the Intralipid/heparin study compared with saline (28+/-4 versus 21+/-3 mg/kg per day; P=0.020). CONCLUSIONS This is the first study to demonstrate that intestinal TRL apoB-48 production is increased after short-term elevation of plasma FFAs in humans in the fed state, similar to the well-described stimulation of hepatic TRL apoB100-containing particles by FFAs.
Collapse
Affiliation(s)
- Hélène Duez
- Department of Medicine, Division of Endocrinology and Metabolism, University of Toronto, Toronto, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Duez H, Lamarche B, Valéro R, Pavlic M, Proctor S, Xiao C, Szeto L, Patterson BW, Lewis GF. Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation 2008; 117:2369-76. [PMID: 18443237 DOI: 10.1161/circulationaha.107.739888] [Citation(s) in RCA: 93] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
BACKGROUND Hepatic lipoprotein production has been shown previously to be regulated by free fatty acid (FFA) flux to the liver, whereas intestinal lipoprotein production is stimulated mainly by ingested fat absorbed from the intestinal lumen. Emerging evidence indicates that intestinal lipoprotein production is increased in insulin resistance and type 2 diabetes mellitus, conditions that are associated with increased levels of circulating FFAs. Here we investigated whether short-term elevation of plasma FFAs stimulates intestinal apolipoprotein (apo) B-48- and hepatic apoB-100-containing triglyceride-rich lipoprotein (TRL) production in humans in the fed state. METHODS AND RESULTS TRL apoB-48 and apoB-100 metabolism were examined in 12 healthy men during a constant fed state. The studies were as follows, respectively: (1) Intralipid/heparin was infused intravenously immediately before and during the kinetics study to induce an approximately 3-fold difference in plasma FFA compared with the saline study; (2) saline was infused intravenously as a control. ApoB-48- and apoB-100-containing TRL production and clearance were determined with a 12-hour primed constant infusion of [D3]L-leucine and multicompartmental kinetic modeling. TRL apoB-48 production rate was 69% higher in the Intralipid/heparin study than in the saline control (5.95+/-1.13 versus 3.53+/-0.58 mg/kg per day; P=0.027), and there was no significant difference in TRL apoB-48 clearance. TRL apoB-100 concentrations were also increased (P<0.001) and TRL apoB-100 production rate was 35% higher in the Intralipid/heparin study compared with saline (28+/-4 versus 21+/-3 mg/kg per day; P=0.020). CONCLUSIONS This is the first study to demonstrate that intestinal TRL apoB-48 production is increased after short-term elevation of plasma FFAs in humans in the fed state, similar to the well-described stimulation of hepatic TRL apoB100-containing particles by FFAs.
Collapse
Affiliation(s)
- Hélène Duez
- Department of Medicine, Division of Endocrinology and Metabolism, University of Toronto, Toronto, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Abstract
Normal physiological processes are under control of circadian rhythms. Moreover, certain pathological events, such as cardiovascular accidents (myocardial infarction, stroke) occur more frequently at specific times of the day. Recent observations demonstrate a causal relationship between alterations in circadian rhythmicity and metabolic disorders. Disruption of clock genes results in dyslipidemia, insulin resistance and obesity, all predisposing to atherosclerosis. The nuclear receptor Rev-erb alpha is part of the clock circuitry and plays an important role in keeping proper timing of the clock. Rev-erb alpha also regulates lipid metabolism, adipogenesis and vascular inflammation. Interestingly, Rev-erb alpha also cross-talks with several other nuclear receptors involved in energy homeostasis. Therefore Rev-erb alpha may serve to couple metabolic and circadian signals.
Collapse
Affiliation(s)
- Hélène Duez
- Institut Pasteur de Lille, Lille F-59019, France
| | | |
Collapse
|
49
|
Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler Thromb Vasc Biol 2006; 26:1357-63. [PMID: 16614317 DOI: 10.1161/01.atv.0000222015.76038.14] [Citation(s) in RCA: 137] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Whereas postprandial hyperlipidemia is a well-described feature of insulin-resistant states and type 2 diabetes, no previous studies have examined intestinal lipoprotein production rates (PRs) in relation to hyperinsulinemia or insulin resistance in humans. METHODS AND RESULTS Apolipoprotein B-48 (apoB-48)-containing lipoprotein metabolism was examined in the steady-state fed condition with a 15-hour primed constant infusion of [D3]-l-leucine in 14 nondiabetic men with a broad range of body mass index (BMI) and insulin sensitivity. To examine the relationship between indices of insulin resistance and intestinal lipoprotein PR data were analyzed in 2 ways: by correlation and by comparing apoB-48 PRs in those whose fasting plasma insulin concentrations were above or below the median for the 14 subjects studied (60 pmol/L). ApoB-48 PR was significantly higher in hyperinsulinemic, insulin-resistant subjects (1.73+/-0.39 versus 0.88+/-0.13 mg/kg per day; P<0.05) and correlated with fasting plasma insulin concentrations (r=0.558; P=0.038), despite great heterogeneity in apoB-48 kinetic parameters, particularly among the obese subjects. There was no significant difference in clearance of apoB-48 between the 2 groups, nor was there a significant correlation between apoB-48 fractional clearance rate and fasting insulin or homeostasis model assessment-insulin resistance. CONCLUSIONS These are the first human data to conclusively demonstrate that intestinal apoB-48-containing triglyceride-rich lipoprotein PR is increased in hyperinsulinemic, insulin-resistant humans. Intestinal lipoprotein particle overproduction is a newly described feature of insulin resistance in humans.
Collapse
Affiliation(s)
- Hélène Duez
- Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Ontario, Canada
| | | | | | | | | | | |
Collapse
|
50
|
Duez H, Lefebvre B, Poulain P, Torra IP, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, Dzavik V, Fruchart JC, Fiévet C, Lefebvre P, Staels B. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol 2004; 25:585-91. [PMID: 15618549 DOI: 10.1161/01.atv.0000154140.73570.00] [Citation(s) in RCA: 93] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE The objective of this trial was to study the effects of fenofibrate (FF) and gemfibrozil (GF), the most commonly used fibrates, on high-density lipoprotein (HDL) and apolipoprotein (apo) A-I. METHODS AND RESULTS In a head-to-head double-blind clinical trial, both FF and GF decreased triglycerides and increased HDL cholesterol levels to a similar extent, whereas plasma apoA-I only increased after FF but not GF. Results in human (h) apoA-Itransgenic (hA-ITg) peroxisome proliferator-activated receptor (PPAR) alpha-/- mice demonstrated that PPARalpha mediates the effects of FF and GF on HDL in vivo. Although plasma and hepatic mRNA levels of hapoA-I increased more pronouncedly after FF than GF in hA-ITgPPARalpha+/+ mice, both fibrates induced acylCoAoxidase mRNA similarly. FF and GF transactivated PPARalpha with similar activity and affinity on a DR-1 PPAR response element, but maximal activation on the hapoA-I DR-2 PPAR response element was significantly lower for GF than for FF. Moreover, GF induced recruitment of the coactivator DRIP205 on the DR-2 site less efficiently than did FF. CONCLUSIONS Both GF and FF exert their effects on HDL through PPARalpha. Whereas FF behaves as a full agonist, GF appears to act as a partial agonist due to a differential recruitment of coactivators to the promoter. These observations provide an explanation for the differences in the activity of these fibrates on apoA-I.
Collapse
Affiliation(s)
- Hélène Duez
- UR545INSERM, Département d'Athérosclérose, Institut Pasteur Lille and Faculté de Pharmacie, Université de Lille2, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|